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Summary 
 
Spinocerebellar Ataxia Type 3 (SCA3) is an inherited, neurodegenerative disorder 
belonging to the group of polyglutamine repeat disorders. It is caused by CAG repeat 
expansions in the ATXN3 gene leading to expanded polyglutamine repeats in the 
ATXN3 protein. The expanded ATXN3 protein forms intranuclear inclusions in 
neuronal cells ultimately leading to neuronal death. MicroRNAs are endogenously 
produced, small, non-coding RNAs that play a role in post-transcriptional regulation of 
gene expression. MicroRNA mediated regulation of gene expression is associated with 
several processes such as the development of organisms, maintenance of homeostasis 
as well as with several human disorders such as cancer and neurodegenerative 
diseases.   
The present study demonstrates the ability of specific microRNAs to target the 
expression of the proteins ATXN3, MID1 and DNAJB1 which play important roles in 
the pathogenic mechanisms in SCA3. The microRNAs hsa-miR-32 and hsa-miR-181c 
were found to target and reduce ATXN3 expression, while hsa-miR-216a-5p, hsa-
miR-374a-5p, hsa-miR-542a-3p target and reduce the expression of MID1. Profiling of 
gene and microRNA expression in iPSC-derived neurons from SCA3 patients and 
controls revealed that in SCA3 neurons, hsa-miR-370 and hsa-miR-543 that target the 
expression of the neuroprotective DNAJB1 chaperone are upregulated, while the target 
DNAJB1 mRNA and protein are downregulated. Similarly, DNAJB1 mRNA level was 
found to be downregulated in a transgenic SCA3 mouse model suggesting that the 
miRNA mediated reduction in the neuroprotective DNAJB1 might contribute to the 
pathogenesis observed in SCA3.    
These results demonstrate the two sided role of microRNAs in the pathogenesis of 
SCA3 by targeting the expression of neurotoxic proteins such as ATXN3, MID1 as 
well as neuroprotective proteins such as DNAJB1. The findings of this study might 
contribute towards miRNA based therapeutic strategies such as enhancing miRNA 
targeting of neurotoxic proteins and preventing miRNA targeting of neuroprotective 
proteins.  
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Chapter 1 Introduction 
 
1.1 Trinucleotide repeat disorders 
Trinucleotide repeat disorders are a class of inherited, neurological disorders characterized 
by expansions of trinucleotide repeats. With 16 disorders, they form the largest group of 
inherited neurodegenerative diseases. The trinucleotide expansions are unstable and 
studies have shown that the number of trinucleotide repeats might increase in successive 
generations (Fu et al, 1991). These mutations are therefore termed as ‘dynamic’ mutations.  
Since the severity of symptoms and the age of onset are dependent on the number of 
trinucleotide repeats, the instability of the repeats explains the variability of the symptoms 
and the age of onset (Orr & Zoghbi, 2007). The exact trinucleotide sequence that is 
expanded and the pathogenic mechanism vary amongst the trinucleotide disorders. For 
example CTG expansions in the DMPK gene cause Myotonic Dystrophy type 1 (DM1) 
where the expanded mRNA mediates the pathogenicity (Mankodi et al, 2002). CGG 
expansions in the FMR1 gene cause Fragile X syndrome (FXTAS) where the pathogenesis 
is mediated by an inability of the FMR1 gene to be expressed into FMRP protein (Pieretti 
et al, 1991). Relevant to this study are the CAG repeat disorders where the expanded 
polyglutamine chain coded by CAG repeat expansions mediates the pathogenesis.   
 
1.2 Polyglutamine repeat diseases 
Polyglutamine (PolyQ) diseases are a subset of the trinucleotide repeat disorders where 
expansions of the trinucleotide repeat CAG occur in the coding regions of various genes. 
Since CAG codes for the amino acid glutamine, these diseases are characterized by 
expanded glutamine repeats in the mutant proteins. Except for the presence of 
polyglutamine repeats, these proteins are unrelated (La Spada et al, 1994; Zoghbi & Orr, 
2000).   
A hallmark of all these diseases is the formation of intraneuronal inclusions, which 
primarily include the expanded polyglutamine proteins, but in which several other proteins 
such as ubiquitin and components of the proteasome are sequestered (Davies et al, 1998; 
Ross, 1997; Rubinsztein et al, 1999). The neurons that develop intraneuronal inclusions 
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vary between the different polyglutamine diseases; this results in a pattern of atrophy that 
is unique for each polyglutamine disease, and also explains the differential symptoms seen 
in each disease. The exact mechanism through which the presence of these mutant proteins 
leads to neuronal death is not yet known. Several mechanisms such as proteolytic cleavage 
of the mutant protein, shuttling of the mutant protein to the nucleus and its subsequent 
aggregation, failure to clear the mutant protein as well as mitochondrial dysfunction have 
been shown to contribute to the observed neuronal death (Weber et al, 2014). As of now 
there are nine polyglutamine diseases known. Table 1.1 gives an overview of the genes 
mutated, the resultant proteins and the CAG repeat expansions associated with each 
polyglutamine disorder. Amongst the polyglutamine diseases one of the best studied is the 
most prevalent of the inherited ataxias, the Spinocerebellar Ataxia type 3 (SCA3) that is 
also the disorder studied in this project. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction     
3 
 
Disease Gene Protein CAG repeats in 
Wild type Mutant 
Spinocerebellar 
Ataxia type 1 (SCA1) 
ATXN1 Ataxin 1 8-44 39-83 
Spinocerebellar 
Ataxia type 2 (SCA2) 
ATXN2 Ataxin 2 13-31 32-79 
Spinocerebellar 
Ataxia type 3 (SCA3) 
ATXN3 Ataxin 3 12-40 55-84 
Spinocerebellar 
Ataxia type 6 (SCA6) 
CACNA1A α-voltage dependent 
calcium channel 
subunit 
4-18 19-33 
Spinocerebellar 
Ataxia type 7 (SCA7) 
ATXN7 Ataxin 7 4-35 37-306 
Spinocerebellar 
Ataxia type 17 
(SCA17) 
TBP TATA-binding 
protein 
25-44 47-63 
Huntington’s Disease 
(HD) 
HTT Huntingtin 6-35 36-121 
Spinal-bulbar 
muscular atrophy 
(SBMA) 
AR Androgen receptor 10-36 38-62 
Dentatorubral-
pallidoluysian 
atrophy (DRPLA) 
ATN1 Atrophin 1 7-23 47-55 
Table 1.1: An overview of the nine polyglutamine diseases. Listed above are the mutant 
genes and the resultant proteins alongside the CAG repeats associated with wild type and 
mutant alleles.  
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1.3 Spinocerebellar Ataxia type 3 (SCA3) 
SCA3 is also known as Machado Joseph disease (MJD), named after Portuguese families 
originating from the Azores islands in whose members the symptoms of the disease were 
first described. Initially MJD and SCA3 were thought of as two different diseases with 
similar symptoms. It was only when the genetic locus of both these inherited diseases was 
discovered to be located in the same region of chromosome 14 that consensus was reached 
that both these diseases constitute a single disorder encompassing a rather heterogeneous 
group of symptoms (Kawaguchi et al, 1994; Stevanin et al, 1994; Twist et al, 1995). After 
initial studies in descendants from Portuguese ancestry, in the middle of the 1990s SCA3 
was increasingly described in patients from several countries such as Japan, China, and 
Germany etc. thus widening the scope of its study (Schols et al, 1996; Soong et al, 1997; 
Takiyama et al, 1995). In several regions of the world SCA3 is the most prevalent of the 
dominant spinocerebellar ataxias (Schols et al, 1996; Trott et al, 2006; Watanabe et al, 
1998). 
The symptoms of SCA3 are heterogeneous, with deficits of the cerebellar, pyramidal, 
extrapyramidal systems seen to various degrees. The most common associated symptoms 
include cerebellar ataxia, opthalmoplegia (paralysis of eye muscles), bulging eyes, 
dystonia, incontinence, weight loss and involuntary contractions of the facial muscles. 
Owing to the heterogeneity, the symptoms have been grouped into 4 subgroups to aid in 
diagnosis. The type of symptoms and the age of onset are correlated to the number of 
CAG repeats in the expanded ATXN3 gene, with the mean age of onset around 36 years 
(Durr et al, 1996; Riess et al, 2008). 
The neuropathology of SCA3 is associated with degeneration and atrophy in the 
cerebellum, thalamus, parts of the midbrain, pons, medulla oblongata and basal ganglia.  
The neuronal loss affects the nuclei of oculomotor, vestibular, somatomotor and ingestion-
related loops (Durr et al, 1996; Rub et al, 2013; Seidel et al, 2012b). 
 
 
 
 
Introduction     
5 
 
1.4 ATXN3 gene 
The ATXN3 gene is present on chromosome 14 in humans. Its sequence is evolutionarily 
conserved as sequences homologous to human ATXN3 have been found in the animal 
genomes such as mouse, rat, Drosophila, C.elegans as well as the plant genomes of 
A.thaliana and rice (Albrecht et al, 2003). The ATXN3 gene has 11 exons and the ATXN3 
mRNA has several splice variants (Ichikawa et al, 2001) (Fig 1.1). In humans, healthy 
individuals have up to 44 CAG repeats in the ATXN3 gene whereas SCA3 patients have 
between 52-86 CAG repeats. Individuals with 45-51 CAG repeats might or might not 
develop the disease, a phenomenon known as incomplete penetrance. Individuals with 
CAG repeats more than 55 definitely develop SCA3 (Todd & Paulson, 2010). 
 
Figure 1.1: Structure of the ATXN3 gene, mRNA and protein. Exons are denoted in 
dark blue, introns in grey and the untranslated regions in light blue. As seen in (a) the 
ATXN3 gene is composed of a total of 11 exons interspersed by introns that are omitted in 
the ATXN3 mRNA (b). The initial 7 exons code for the Josephin domain in the ATXN3 
protein, the rest of the exons code for the C-terminal domain with the polyQ chain 
encoded by the 10
th
 exon (c). 
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1.5 ATXN3 protein 
The ATXN3 protein is encoded by the ATXN3 gene. In humans ATXN3 is expressed 
throughout the body primarily as a cytoplasmic protein, although it is also present in the 
nucleus and the mitochondria to some extent. It is widely expressed in the brain, even in 
areas which are unaffected by SCA3 (Paulson et al, 1997a) (Trottier et al, 1998). The wild 
type ATXN3 has a molecular weight of 42 kDa, whereas the molecular weight of the 
mutant protein is increased considerably due to the expanded polyglutamine chain. 
Structural studies have elucidated that ATXN3 is made up of a globular N-terminal 
domain known as the Josephin domain and an unstructured C-terminal domain that 
contains the polyglutamine repeat tract (Masino et al, 2003) (Fig 1.1). The Josephin 
domain has two ubiquitin binding sites and has ubiquitin protease activity (Chow et al, 
2004; Nicastro et al, 2009) whereas the C-terminal domain has ubiquitin interacting motifs 
(UIMs) which define the specificity of the Josephin domain to cleave ubiquitin chains 
having linkages at Lys
63 
(Winborn et al, 2008). 
ATXN3 functions as a ubiquitin protease and binds to poly-ubiquitylated proteins 
especially ones with four or more ubiquitins in chain through a specific domain known as 
the Ubiquitin Interacting Motif (UIM) (Burnett et al, 2003; Chai et al, 2004; Donaldson et 
al, 2003; Doss-Pepe et al, 2003). Analysis of the structure of the Josephin domain also 
revealed that ATXN3 belongs to the family of papain-like cysteine proteases (Nicastro et 
al, 2005). Besides, ATXN3 has been shown to interact with chromatin via histone binding 
and function as a transcriptional co-repressor, whereby it controls the transcription of 
several genes including genes coding for cell surface-associated proteins (Evert et al, 
2006; Evert et al, 2003; Li et al, 2002).  
The cell toxicity mediated by expanded ATXN3 is triggered by its proteolytic cleavage to 
form an aggregate prone fragment; a phenomenon seen in several polyQ disorders and 
called the toxic fragment hypothesis (Wellington et al, 1998). The expanded ATXN3 is 
cleaved by calcium dependent calpain proteases to form an aggregation prone C-terminal 
fragment containing the expanded polyglutamine stretch that is enough to induce 
aggregation and cell toxicity (Haacke et al, 2006; Haacke et al, 2007; Ikeda et al, 1996). 
The expanded ATXN3 fragment forms intranuclear inclusions (NIs) in neurons in affected 
brain regions in which several other proteins are recruited and sequestered including the 
full-length ATXN3 (Paulson et al, 1997b; Schmidt et al, 1998). Other proteins shown to be 
Introduction     
7 
 
recruited into the NIs are polyglutamine repeat containing proteins such as the TATA-
binding protein (TBP), Eyes Absent (EYA) protein in a Drosophila model of SCA3 (Perez 
et al, 1998), several proteins that bind to ATXN3 such as the transcriptional co-activator 
CREB-binding protein (CBP) (McCampbell et al, 2000), human homolog of the yeast 
DNA repair protein HHR23 (Wang et al, 2000) as well as the 26 proteasome (Chai et al, 
1999b) and ubiquitin (Schmidt et al, 1998). This recruitment and sequestration of proteins 
might be accompanied with a partial or complete loss of their function thereby 
contributing to the cell toxicity. Since the inclusions are formed only in the nucleus, the 
localization of the expanded ATXN3 to the nucleus is key to the aggregation-mediated 
toxicity (Bichelmeier et al, 2007). Other studies have documented the involvement of a 
variety of mechanisms and pathways that might mediate toxicity in SCA3. These include 
the downregulation of autophagy (Menzies et al, 2010; Nascimento-Ferreira et al, 2011), 
oxidative stress leading to mitochondrial dysfunction (Tsai et al, 2004; Yu et al, 2009), 
inflammation (Evert et al, 2001). 
It is worth mentioning that although the main body of research has shown that aggregates 
mediate toxicity in polyQ diseases, there is also evidence on the contrary, i.e. the 
oligomeric fractions of the polyQ proteins mediate toxicity whereas aggregate formation 
serves to limit the amount of oligomers in the cells (Arrasate et al, 2004; Lajoie & Snapp, 
2010; Leitman et al, 2013). The question of whether oligomeric fraction or the aggregates 
form the basis of toxicity in SCA3 is as yet still open to debate. 
Several animal models have been established to study the molecular mechanism, 
pathogenesis and phenotypic effects of the expression of expanded ATXN3, either full 
length or just the pathogenic, aggregate prone fragment. Owing to the conservation of 
basic cellular pathways and mechanisms, transgenic Drosophila and C.elegans expressing 
the expanded human ATXN3 transgene have been instrumental in understanding the 
pathogenic mechanisms associated with SCA3 (Teixeira-Castro et al, 2011; Warrick et al, 
1998). A number of transgenic mouse models have been shown to exhibit phenotypic 
effects such as gait abnormalities and progressive ataxia, along with cerebellar 
neurodegeneration and the presence of intranuclear inclusions (Cemal et al, 2002; Chou et 
al, 2008; Ikeda et al, 1996). A conditional knockout model of SCA3 transgenic mice 
exhibited a progressive neurological phenotype, which could be reversed by turning off 
the expression of mutant ATXN3 in early stages of the disease (Boy et al, 2009). 
Alternately, SCA3 models created by injecting lentiviral vectors expressing the expanded 
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ATXN3 into either rats or mice also exhibited the hallmarks of SCA3, i.e. formation of 
intranuclear inclusions and progressive neuronal cell loss (Alves et al, 2008; Nobrega et al, 
2013). A recent development is the preparation of iPSCs (Induced Pluripotent Stem Cells) 
from fibroblasts from SCA3 patients. Neurons derived from these iPSCs exhibit the 
formation of aggregates following calpain-mediated cleavage induced by glutamate 
excitation (Koch et al, 2011).  
Research into deciphering the molecular mechanisms of SCA3 and other polyQ diseases 
revealed the role of several proteins in the pathogenesis and disease progression of these 
diseases. Two of these proteins: namely the chaperone DNAJB1 (HSP40) and the CAG 
repeat mRNA interacting protein MID1, are also a part of the current study.   
 
1.6 DNAJB1 
Molecular chaperones are proteins that play an important role in maintaining protein 
homeostasis in the cell by aiding the process of proper folding of proteins and thereby 
preventing the accumulation of misfolded proteins and protein aggregates in the cell. One 
of the earliest publications to define this category of proteins, defines molecular 
chaperones as “proteins whose role is to mediate the folding of certain other polypeptides 
and, in some instances, their assembly into oligomeric structures, but which are not 
components of these final structures” (Ellis & Hemmingsen, 1989). Importance of the role 
of chaperones in maintaining proteostasis can be gauged from the fact that homologues of 
the chaperone proteins can be found in archaebacteria, eubacteria as well as eukaryotes 
with partial conservation of gene sequences across the evolutionary ladder (Bardwell & 
Craig, 1984). An important group of chaperones are heat shock proteins (HSPs), which 
were initially discovered to be expressed in response to heat shock (Lindquist, 1986). 
Gradually it was found that a.) HSPs are expressed in response to other stresses apart from 
heat stress (Lanks, 1986; Whelan & Hightower, 1985) and b.) certain HSPs are also 
expressed under non-stress conditions (Ingolia & Craig, 1982). Amongst the HSPs, an 
important group are the Heat Shock Protein 70 (HSP70) proteins, named so due to their 
size, which is approximately 70 kDa. HSP70 proteins mediate the refolding of proteins in 
eukaryotes, while their bacterial counterpart, the protein DnaK, which bears a partial 
sequence similarity to HSP70 mediates protein refolding in bacteria (Bardwell & Craig, 
1984).  Certain members of the HSP70 group are expressed in response to stress, whereas 
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some such as Hsc70 are expressed constitutively under non stress conditions (Ingolia & 
Craig, 1982).  The HSP70 proteins however are not able to refold proteins alone. In 1990 
Ohtsuka and colleagues described for the first time a 40 kDa protein, which was expressed 
in cells along with HSP70 in response to stress (Ohtsuka et al, 1990). Further studies 
elucidated that this protein, named HSP40 or HDJ-1 since it bears a partial sequence 
similarity to the bacterial DnaJ chaperone, is a mammalian homologue of the Dnaj whose 
association with the DnaK in bacteria is essential for the chaperone function of DnaK 
(Hattori et al, 1992; Ohtsuka, 1993; Raabe & Manley, 1991). Proof of the co-chaperone 
function of HDJ-1 was found when it was discovered that it physically interacts with 
HSP70 and in the presence of ATP this complex is able to refold a substrate, which is 
normally a misfolded protein or an unfolded protein intermediate (Freeman & Morimoto, 
1996; Freeman et al, 1995; Sugito et al, 1995). The HSP70-HSP40 machinery was found 
to be active in the nucleus as well as the cytoplasm (Michels et al, 1997). Subsequently it 
was found that HDJ-1 is just one of several HSP40 proteins which comprise the DNAJ 
group of co-chaperones, characterized by the presence of a ‘J-domain’ through which they 
interact with the HSP70 chaperones. Although studies have shown that several members 
of the DNAJ family potentially play a role in the aggregation of polyglutamine expanded 
proteins, one member, DNAJB1 has been of particular interest since a majority of studies 
have found it to be the dominant member of the DNAJ family associated with 
polyglutamine aggregates in cells.  
 
1.7 DNAJB1 in polyglutamine diseases 
The phenomenon of aggregation is seen in several diseases where mutations in genes 
render the mutated proteins unable to fold in the appropriate way. In many cases these 
aggregates contain not only the misfolded protein but also other interacting proteins and 
components of the proteasome machinery such as ubiquitin, subunits of the proteasome 
and chaperones, which try to clear these aggregates (Chai et al, 1999b; Schmidt et al, 
1998). The HSP70-HSP40 chaperones have been found to be co-localized with protein 
aggregates seen in several inherited disorders such as the mutant SOD1 aggregates in 
familial ALS (Takeuchi et al, 2002), mutant transcription factor Hoxd13 with poly-alanine 
repeat expansions (Albrecht et al, 2004) as well as mutant proteins with polyglutamine 
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repeats such as androgen receptor (AR) (Bailey et al, 2002),  ATXN1 (Cummings et al, 
1998), ATXN3 (Chai et al, 1999a) and huntingtin (Muchowski et al, 2000).  
Although some studies have implicated other members of the DNAJ family as the co-
chaperones associated with HSP70 during interactions with polyglutamine mediated 
aggregates, the majority of the studies have exhibited that the DNAJB1 is the active 
HSP40 co-chaperone that binds to HSP70 in such interactions. The HSP70-HSP40 
chaperones seem to bind to polyQ aggregates and prevent the propagation of the fibril like 
detergent insoluble aggregates, forming detergent soluble amorphous aggregates that are 
also less toxic (Muchowski et al, 2000). Several cell culture studies have shown that the 
overexpression of the DNAJB1 chaperone suppresses polyQ aggregate formation and the 
associated cell toxicity (Chai et al, 1999a; Jana et al, 2000). The underlying mechanism is 
thought to be that the DNAJB1 recognizes and binds to the misfolded polyQ protein and 
attempts to refold it in such a way that it is recognized by the HSP70. HSP70 then binds to 
the protein and, in an ATP dependent reaction converts it into a less toxic form that can be 
degraded (Lotz et al, 2010; Rujano et al, 2007). The yeast homologue of DNAJB1, Sis1p 
is sequestered by polyQ-expanded proteins, thus rendering it unable to perform its 
function of binding and transporting misfolded proteins to the nucleus for proteasomal 
degradation. As a result the misfolded proteins form toxic, cytoplasmic aggregates (Park et 
al, 2013). A similar phenomenon was observed in neurons from SCA3 patients where 
DNAJB1 co-localized with the intranuclear inclusions and was markedly decreased from 
the cytoplasm (Seidel et al, 2012a). Along with other HSP40 chaperones it was found that 
the differential expression of DNAJB1 seems to play a role in the CAG independent age of 
onset of symptoms in SCA3 patients (Zijlstra et al, 2010).  
 
1.8 MID1 
The MID1 protein encoded by the MID1 gene is an E3 ubiquitin ligase (Quaderi et al, 
1997; Trockenbacher et al, 2001). It associates with microtubules and has been shown to 
bind and regulate the activity of several proteins as well as mRNAs, including CAG repeat 
mRNAs (Krauss et al, 2013; Schweiger et al, 1999). MID1 binds to Protein Phosphatase 
2A (PP2Ac) via its alpha-4 subunit and regulates its activity by mediating its degradation 
by the proteasome (Liu et al, 2001; Trockenbacher et al, 2001). Since the protein mTOR 
Kinase is a target of PP2A, MID1 indirectly also regulates the activity of mTOR (Liu et al, 
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2011). PP2A and mTOR together regulate mRNA translation in cells by regulating the 
phosphorylation of proteins such as ribosomal S6 kinase (S6K), which further targets 
proteins important for translation such as elongation factor 4B (elF4B) and ribosomal S6 
(Holz et al, 2005). Further proof that MID1 plays a crucial role in translation regulation is 
provided by findings that MID1 binds to proteins associated with mRNA transport and 
translation as well as mRNAs, which have a specific motif known as a MIDAS motif 
(Aranda-Orgilles et al, 2011; Aranda-Orgilles et al, 2008). Thus it forms a 
ribonucleoprotein complex at the microtubules and mediates the translation of specific 
mRNAs at the microtubules. This mechanism suggests that MID1 might play a crucial role 
in neurons, where translation in axons would probably be preceded by mRNA transport 
along the microtubules. Apart from these findings, which exhibit the importance of MID1 
in translation, the most important finding relevant to this study is the one that MID1 along 
with PP2A and S6K is able to bind to the CAG repeat region of HTT mRNA in a repeat-
length dependent manner. This binding has an effect on augmenting the translation of the 
CAG repeat RNA into the HTT protein with expanded polyglutamine repeats (Krauss et 
al, 2013).  Also, a recent study has elucidated that MID1 binds to the AR mRNA at the 
CAG repeats and that the overexpression of MID1 leads to increased levels of the AR 
protein while the levels of AR mRNA remain unchanged (Kohler et al, 2014). Figure 1.2 
gives an overview of the role of MID1 in mRNA translation via the various mechanisms 
described above. 
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Figure 1.2: Various mechanisms through which MID1 protein enhances mRNA 
translation. MID1 binds and regulates PP2A through its α-4 subunit, thereby indirectly 
enhancing mTOR activity leading to increased mRNA translation. MID1 binds to 
expanded CAG repeat RNAs leading to enhancement of their translation and forms a 
ribonucleoprotein complex at the microtubules enhancing mRNA translation at the 
microtubules.   
 
In SCA3, a crucial aspect in disease progression and neuronal death is the level of 
expression of the mutant ATXN3, apart from other proteins involved: including DNAJB1 
and MID1. An important mechanism in cells to regulate protein expression is the RNA 
interference machinery, of which microRNAs (miRNAs) form a vital part. miRNAs might 
play a role in SCA3 pathogenesis, and therefore are worth giving attention to. 
 
1.9 MicroRNAs 
It was in the last decade of the 20
th
 century after Andrew Fire and colleagues first 
published their results documenting the presence of double stranded RNA being able to 
interfere with the expression of genes in C.elegans (Fire et al, 1998) that the field of RNA 
interference came alive. Soon, Hamilton and colleagues proved that antisense RNAs 
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regulating gene expression are also present in plants (Hamilton & Baulcombe, 1999) while 
Tuschl et al. observed RNA interference mediated by double stranded RNAs in 
Drosophila (Tuschl et al, 1999). It was soon discovered that RNA interference is mediated 
by a ribonucleoprotein complex that includes short RNAs which confer specificity for the 
target mRNA (Elbashir et al, 2001; Hammond et al, 2000; Zamore et al, 2000) 
MicroRNAs are endogenously produced, non-coding RNAs that are a part of the RNA 
interference machinery of the cell (Lagos-Quintana et al, 2001). miRNAs share partial 
sequence complementarity with their ‘target’ sequences present on mRNAs, mostly in the 
3’ untranslated region (3’UTR) of the mRNAs (Lai, 2002). miRNAs in association with a 
protein complex known as the miRISC (miRNA associated RNA Induced Silencing 
Complex) bind to the above mentioned complementary sequences on their ‘target’ 
mRNAs. This binding either blocks the translation of the mRNA or leads to its 
degradation (Hutvagner & Zamore, 2002); in either way regulating the expression of the 
protein coded by the target mRNA. miRNAs have been found to play important roles in 
plants (Palatnik et al, 2003; Reinhart et al, 2002), C.elegans (Lau et al, 2001; Lee & 
Ambros, 2001; Lim et al, 2003), Drosophila (Xu et al, 2003) and in mammals (Chen et al, 
2004; Lagos-Quintana et al, 2002). miRNAs are estimated to target upto 30% genes in the 
human genome (Lewis et al, 2005). As such miRNAs have been shown to play crucial 
roles in several important pathways in the development of organisms (Houbaviy et al, 
2003; Krichevsky et al, 2003; Lim et al, 2003; Pasquinelli & Ruvkun, 2002; Sempere et al, 
2004) as well as in several important diseases such as cancer, heart disease, 
neurodegenerative diseases etc. An indication of their importance in translational 
regulation can be found from the fact that miRNA sequences and their binding sites on the 
mRNAs are evolutionarily conserved. miRNAs are transcribed from miRNA coding genes 
as well as from introns into several hundred nucleotide long primary miRNA transcripts in 
the cell nucleus (Lee et al, 2002) (Fig 1.3). These transcripts serve as templates for the 
RNAses Drosha and its cofactor Pasha, which cleave these transcripts into premature 70-
80 nucleotide long miRNAs (pre-miRNAs) (Lee et al, 2003). The pre-miRs are exported 
from the nucleus into the cytoplasm via the exportin complex (Lund et al, 2004; Yi et al, 
2003). In the cytoplasm, the pre-miRNAs are further cleaved by the RNAse Dicer to form 
a duplex of miRNAs (Bernstein et al, 2001). Of this duplex, one strand (the guide strand) 
eventually associates with miRISC and plays a role in translational repression of mRNAs. 
The other strand (passenger strand or * strand) has a far less probability of being 
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associated with the miRISC complex (Schwarz et al, 2003). miRNA binding sites on the 
target mRNAs are mostly situated in the 3’ untranslated region (3’ UTR). However, recent 
research seems to suggest that miRNA recognition and binding sites are also present in the 
5’ untranslated region (5’ UTR) as well as in the coding region (Duursma et al, 2008; 
Forman et al, 2008; Lytle et al, 2007).  
 
 
Figure 1.3: Schematic showing the miRNA biogenesis pathway. Primary miRNAs are 
transcribed in the nucleus by RNA polymerase II. Upon cleavage by Drosha/Pasha the 
precursor miRNAs are exported to the cytosol where further cleavage by Dicer leaves the 
miRNA duplex. The guide strand associates with the RISC complex to participate in 
translation repression. 
 
1.10 MicroRNAs in neurodegenerative diseases 
Several studies have shown that miRNAs play an important role in maintaining the 
homeostasis of neurons over time and modulations in miRNA levels and pathways also 
contribute towards the effects of aging in the brain. For example, it was seen that the 
ablation of the enzyme Dicer (important for miRNA maturation) in Purkinje cells in mice 
led to a gradual decrease in levels of certain miRNAs accompanied by development of 
ataxia and eventually Purkinje neuron death (Schaefer et al, 2007). Experiments in 
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Drosophila uncovered that a miRNA, the miR-34 is essential for a normal lifespan and 
prevents untimely ageing (Liu et al, 2012). Various miRNAs have also been shown to play 
a role in the pathogenesis of neurodegenerative diseases such as Alzheimer’s disease 
(Lehmann et al, 2012; Wong et al, 2013), Friedreich Ataxia (Mahishi et al, 2012), Fragile 
X Associated Tremor/Ataxia Syndrome (FXTAS) (Tan et al, 2012; Zongaro et al, 2013). 
With regards to the involvement of miRNAs in polyglutamine diseases, most of the 
research as yet has been in Huntington’s disease. Studies in mouse, primate models of HD, 
as well as HD patients exhibited altered expression of miRNAs and proteins that are either 
involved in miRNA pathways or are probable targets of the altered miRNAs (Jin et al, 
2012; Kocerha et al, 2014; Lee et al, 2011). Many of these miRNAs are regulated by the 
transcriptional repressor REST, which is activated in HD (Johnson et al, 2008; Marti et al, 
2010; Packer et al, 2008). An altered expression of miRNAs and its role in toxicity has 
also been seen in models of SCA1 (Lee et al, 2008; Persengiev et al, 2011; Rodriguez-
Lebron et al, 2013). Not much has as yet been published regarding the role of miRNAs in 
SCA3. In a Drosophila model of SCA3, it was seen that hampered miRNA processing 
brought about by mutation of the Dicer enzyme enhances toxicity associated with the 
expression of mutant ATXN3. A miRNA named Bantam was also found to be vital to 
prevent degeneration (Bilen et al, 2006). 
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Aims of the thesis 
 
SCA3 is an inherited disorder caused by CAG repeat expansions in the ATXN3 gene, 
leading to expanded polyglutamine repeats in the ATXN3 protein coded by this gene. The 
expression of the expanded ATXN3 protein leads to neurotoxicity via several mechanisms 
involving the soluble form as well as the intraneuronal aggregates formed by the mutant 
ATXN3 protein. miRNAs are endogenously produced, non-coding RNAs that play an 
important role in post-translational gene regulation via the RNA interference (RNAi) 
mechanism. miRNAs in association with specific protein complexes block the translation 
or degrade mRNAs by binding at specific target sites mostly on the 3’UTR of the mRNA. 
miRNAs play an important role in maintaining homeostasis and response to stress and 
disease. On the other hand, dysregulation of miRNAs has been shown to be associated 
with several human disorders. 
This study aimed at elucidating the role of miRNAs in SCA3 where the expanded ATXN3 
protein triggers the involvement of multiple proteins and pathways in pathogenesis. 
miRNAs might be differentially expressed in SCA3 cells in response to the metabolic 
stress and protein aggregates to downregulate the expression of mutant ATXN3 and other 
neurotoxic proteins such as MID1 which has been shown to augment the translation of 
mRNAs with expanded CAG repeats. With this consideration, ATXN3 and MID1 were 
chosen as candidate neurotoxic proteins to analyse the ability of miRNAs to target their 
expression. The aim here was to find miRNAs that bind at specific sites on the 3’UTR of 
ATXN3 and MID1 mRNAs and to validate the ability of these miRNAs to regulate the 
mRNA and protein expression of ATXN3 and MID1 in human cell lines. Another aim of 
this study was to elucidate miRNA targeting of gene expression relevant to SCA3 
pathogenesis using iPSC-derived neurons from SCA3 patients and controls. For this 
purpose, gene expression and miRNA expression profiles from iPSC-derived neurons 
were analysed to choose relevant candidate proteins that might be targeted by miRNAs.  
Finally, the study aimed at validation of miRNA targeting of the chosen candidate in terms 
of specific binding, regulation of candidate mRNA and protein expression in human cell 
lines. 
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Chapter 2 Materials and Methods 
 
Section 2.1 Materials 
 
2.1.1 List of consumables 
0.1-5 mL Combitips: Eppendorf Research 
1.5 mL/2 mL safe lock tubes: Sarstedt 
10-1000 μL pipette tips: Nerbeplus 
100/250 mL conical flasks 
15 mL/20 mL Screw cap centrifuge tubes: VWR International 
5/10/25/50 mL serological pipettes: Sarstedt 
8 well glass chamber slide: Lab Tek II, NUNC (154534) 
96-well reaction plate: Applied Biosystems (4306737) 
Disposable hypodermic needle (0.60*30 mm): 100 Sterican, Braun Medical AG 
Filter paper: Bio Rad (cat: 1703969) 
Glass plates (Short/1.0mm spacer): Mini Protean System 
Pasteur pipettes: Carl Roth GmbH 
Petri plates 
PVDF membrane: Roche Diagnostics GmbH (Ref: 03010040001) 
Syringe, 5 mL: Braun Medical AG  
Tissue culture flask: TPP 75 cm
2
 (90075)/150 cm
2 
(90150)
 
 
Tissue culture test plate (12 well): TPP (92012) 
 
2.1.2 List of Devices 
0.2-1000 μL Pipettes: Eppendorf Research 
Agarose gel electrophoresis chamber: Sub-Cell GT (Bio Rad) 
Agarose Gel/Immunoblot imaging system: Stella (Raytest)   
Automatic pipette: Multipette stream (Eppendorf) 
Bacterial culture shaker/incubator: Kuhner Shaker X (Lab Therm) 
Bacterial plates incubator: Binder 
Cell analysis system: CASY (Innovatis) 
Centrifuge for 1.5/2 mL tubes: Heraeus Fresco 21 (Thermo Scientific)  
Centrifuge for 15/50 mL tubes: Heraeus Multifuge X3R (Thermo Scientific) 
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CO2 incubator: Heracell 240i (Thermo Scientific) 
Confocal Laser Scanning microscope: LSM 700 (Zeiss) 
Fluorometer: Qubit (Life Technologies) 
Heating block: Thermomixer comfort (Eppendorf) 
Ice machine: Ziegra Labor 
Laminar Airflow hood: Mars Safety Class 2 (Scanlaf) 
Light microscope: Primovert (Zeiss) 
Luminescence signal plate reader: Envision Plate reader (Perkin Elmer) 
Microwave oven: NN-SD450W (Panasonic) 
PCR Cycler: DNA Engine Dyad (Bio Rad) 
pH meter: SevenEasy (Mettler Toledo) 
Powerpack: Powerpac Universal (Bio Rad) 
Real-time PCR cycler: 7900HT Fast Real-time PCR systems (Applied BioSystems) 
Roller Mixer: Stuart SRT6 
SDS PAGE Blotter: Trans Blot Semi dry Transfer cell (Bio Rad) 
SDS PAGE chamber: Mini Protean Tetra System (Bio-Rad) 
Sonicator: Bandelin Sonoplus 
Ultra Violet Trans illuminator: TL-2000 (Ultra Violet Products) 
Vortex mixer: Vortex Genie 2 (Scientific Industries Inc) 
Water Bath: Type 1083 (GFL) 
Water purification system: Purelab Option-Q (Elga) 
Weighing balance: Type 572 (Kern and Sohn GmbH) 
 
2.1.3 List of chemicals 
Chemical Manufacturer (Catalogue no.) 
2-Mercaptoethanol Sigma Life Science (63689-100ML-F) 
Acetic acid Sigma Aldrich (A6283-500ML) 
Acrylamide-bis 30% (37.5:1) Merck KGaA (1.00639.1000) 
Adenosine 5’ triphosphate disodium salt 
hydrate 
Aldrich Chemistry (A26209-5G) 
Agar  Sigma Aldrich (05040-1KG) 
Agarose peqGOLD (35.1020) 
Albumin, IgG free Carl Roth GmbH (3737.3) 
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Ammonium Persulphate (APS) Sigma (A 3678.100G) 
Bromophenol Blue Sigma Aldrich (B8026-25G) 
Coelenterazine  p.j.k. GmbH (260350) 
Coenzyme A, sodium salt hydrate Sigma (C4780) 
DL-Dithiothreitol Sigma Life Science (43815-5G) 
D-Luciferin sodium salt p.j.k. GmbH (269149) 
DNA ladder 1 kb Thermo Scientific GeneRuler (SM0313) 
DNA ladder 100 bp Thermo Scientific GeneRuler (SM0243) 
DNA loading dye (6x) Fermentas (R0611) 
Dulbecco’s Modified Eagle Medium 
(DMEM) + GlutaMAX 
Gibco (21885-025 500ML) 
Dulbecco’s Phosphate Buffered Saline 
(DPBS) 
Gibco (14190-094) 
Ethylene Diamine TetraAcetic acid 
(EDTA) 
Sigma Aldrich GmbH (03610.1KG) 
Fluoroshield mounting medium with DAPI Sigma (F6057) 
Foetal bovine serum PAN Biotech (1502-P122011) 
Gel Red nucleic acid stain Biotium (41003) 
Glycine Carl Roth GmbH (3790.3) 
Hydrochloric acid (HCl) 32% Carl Roth GmbH (P074.1) 
Hydrogen Peroxide (H2O2) Sigma Aldrich (95299-500ML) 
LB broth powder Sigma Life Science (L7658-1KG) 
Luminol Aldrich Chemistry (123072) 
Magnesium sulphate heptahydrate 
(MgSO4.7H2O) 
Sigma Aldrich (13142-1KG) 
Methanol Carl Roth GmbH (4627.2) 
Opti-MEM Gibco (31985-070) 
Passive Lysis Buffer (5x) Promega (E1941) 
p-Coumaric Acid Sigma Life Sciences (C9008-25G) 
Penicillin-Streptomycin Gibco (15140-122 100ML) 
Protein Standard ladder Bio Rad Precision Plus Kaleidoscope (161-
0375) 
Roti-Phenol Carl Roth GmbH (0038.2) 
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Sodium Chloride (NaCl) Sigma (S30.14-5KG) 
Sodium Dodecyl Sulphate (SDS) 20% 
solution in H2O 
Sigma Life Science (05030-1L-F) 
TEMED Carl Roth GmbH (2367.1) 
Tricine Sigma Life Science (T0377-1KG) 
Tris (hydroxymethyl) aminomethane Sigma Aldrich (252859-500G) 
Trypsin-EDTA Gibco (25300-054 100ML) 
Tryptone Carl Roth GmbH (8952.2) 
Tween-20 Sigma Life Science (P5927-500ML) 
Yeast extract Carl Roth GmbH (2904.3) 
 
2.1.4 Kits used 
Name Manufacturer (Catalogue no.) 
QIAquick PCR purification kit Qiagen (28104) 
QIAquick Gel Extraction kit Qiagen (28706) 
GenElute five-minute plasmid miniprep kit Sigma life science (PFM250-1KT) 
JetStar 2.0 plasmid purification maxikit Genomed GmbH (220020) 
miRVana miRNA isolation kit Ambion (AM 1560) 
RNeasy Plus mini kit Qiagen (74134) 
Qubit Protein Assay kit Life Technologies (Q33212) 
 
 
2.1.5 Buffer recipes 
SDS PAGE sample buffer (2x) 
EDTA 25mM 
Tris 100 mM 
Glycerol 20% 
SDS 4% 
2 Mercaptoethanol 2% 
Bromophenol blue 0.004% 
SDS PAGE buffer (1x) 
Tris 25 mM 
Glycine 190 mM 
SDS 0.1% 
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Blotting buffer (1x) 
Tris 48 mM 
Glycine 44 mM 
SDS 0.04% 
Methanol 20% 
 
Tris Buffered Saline (TBS) (1x) 
Tris 20 mM 
NaCl 150 mM 
pH 7.6  
 
Tris Buffered Saline Tween-20 (1x) 
Tris 20 mM 
NaCl 150 mM 
pH 7.6  
Tween-20 0.1% 
 
Developing solution A 
Luminol (500 mM in DMSO) 1 mL 
0.1M Tris pH 8.0 400 mL 
Developing solution B 
Coumaric acid (7 mM in DMSO) 
Developing solution: 10 mL Solution A + 1 mL Solution B + 5 µL 30% (w/w) H2O2 
 
TAE buffer (1x) 
Tris 40 mM 
Acetic acid 20 mM 
EDTA 1 mM 
 
 
 
 
 
 
 
Materials and Methods     
22 
 
Balanced Salt Solution (BSS) (1x) 
Tris 25 mM 
NaCl 120 mM 
Glucose 15 mM 
KCl 5.4 mM 
CaCl2 1.8 mM 
MgCl2 0.8 mM 
pH 7.4  
 
D-Luciferin buffer (Firefly luciferase substrate) 
Solution A (4x) 
Tricine pH 7.8 120 mM 
MgSO4 15 mM 
ATP 3 mM 
DTT 5 mM 
Coenzyme A 0.27 mM 
Solution B 
D-Luciferin, sodium salt 100 mM 
Working solution of D-Luciferin buffer 
Solution A (4x) 10 mL + Solution B 0.2 mL + 29.8 mL H2O 
 
Coelenterazine buffer (Renilla luciferase substrate) 
50x Stock solution:  Coelenterazine 2 mM in CH3OH 
Working solution: Coelenterazine 0.04 mM in H2O 
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2.1.6 Primers 
 
ATXN3 3‘ UTR amplification primers 
Atxn3_utr1_xho1_for 
Atxn3_utr1_not1_rev 
 
CTATGACTCGAGAAGGCCAGCCACCAGTTC 
TCACGCGGCCGCCAATGGAAAAAGGTAATG 
DNAJB1 3‘ UTR amplification primers 
Dnajb1-utr-for-xho1 
Dnajb1-utr-rev-not1 
 
CCGCGGCTCGAGATAGCTATCTGAGCTCC 
TATCATGCGGCCGCGAGGTTTAGCATCAGTC 
 
MID1 3‘ UTR amplification primers 
MID1UTR1_xho_for 
MID1UTR1_not1_Rev 
 
GATACTCGAGGCGTCTGGCCACATGGAGCT 
CAATGCGGCCGCCTTAATTCATGGACCATTCCAACG 
 
ATXN3 3’ UTR mutagenesis primers 
ATXN3_mir25_For 
ATXN3_mir25_Rev 
TTTTCTTTTTTGAGTGTGCTTTATGTAACATGTCTAAAG 
CTTTAGACATGTTACATAAAGCACACTCAAAAAAGAAAA 
ATXN3_miR181#1_For 
ATXN3_miR181#1_Rev 
TTCCCAGATGCTTTATGAAACTCTTTTCACTTATATC 
GATATAAGTGAAAAGAGTTTCATAAAGCATCTGGGAA 
ATXN3_miR181#2_For 
ATXN3_miR181#2_Rev 
CATACGTACCCACCATGAAACTATGATACATGAAATT 
AATTTCATGTATCATAGTTTCATGGTGGGTACGTATG 
ATXN3_mir125_For 
ATXN3_mir125_Rev 
GCTGCACACATTTTATCACCGAAAGTTTTTTGATCTA 
TAGATCAAAAAACTTTCGGTGATAAAATGTGTGCAGC 
ATXN3_miR9_For 
ATXN3_miR9_Rev 
TCTTCCAAATATTAGCCATTGAGGCATTCAGCAATT 
AATTGCTGAATGCCTCAATGGCTAATATTTGGAAGA 
ATXN3_miR383_For 
ATXN3_miR383_Rev 
TCTTGTGTTGTTTTCTCTGTACACAACTTTTCTGCTAC 
GTAGCAGAAAAGTTGTGTACAGAGAAAACAACACAAGA 
 
 
DNAJB1 3’UTR mutagenesis primers 
DNAJB1_370_1mutFor 
DNAJB1_370_1mutRev 
CATCAGGTGGTGGGAACAGCGTGAAAAGGCATTCCAGTC 
GACTGGAATGCCTTTTCACGCTGTTCCCACCACCTGATG 
 
DNAJB1_370_2mutFor 
DNAJB1_370_2mutRev 
CAATACCTCTCGTTCCAGCGTGACCAAGGGAGCCAGC 
GCTGGCTCCCTTGGTCACGCTGGAACGAGAGGTATTG 
DNAJB1 mir-543 For 
DNAJB1 mir-543 Rev 
GGCTTTCGTACTGCTGAATCATTTCCAGAGCATATAT 
ATATATGCTCTGGAAATGATTCAGCAGTACGAAAGCC 
DNAJB1 miR-449b For 
DNAJB1 miR-449b Rev 
CTCATTGTAAGTTGCCACTGTTAACATGAGACCAAAGT 
ACTTTGGTCTCATGTTAACAGTGGCAACTTACAATGAG 
 
DNAJB1 mir-143 For 
DNAJB1 mir-143 Rev 
TGTCTTCTCTTTGGCCATCAGAAATTGAGAACCTAAA 
TTTAGGTTCTCAATTTCTGATGGCCAAAGAGAAGACA 
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MID1 3’UTR mutagenesis primers 
miR-216_sitemut_for 
miR-216_sitemut_rev 
CTGGAAGAACATTAAGAATGAGTATGCAATTGAAAATAGT 
GACTATTTTCAATTGCATACTCATTCTTAATGTTCTTCCAG 
miR-374_sitemut_for 
miR-374_sitemut_rev 
GCTAGATTCATGCCTCAAAAGTTATTTAAAACAGACCTTTATTAA 
TTAATAAAGGTCTGTTTTAAATAACTTTTGAGGCATGAATCTAGC 
miR-542_sitemut_for 
miR-542_sitemut_rev 
GAGTAAATAAACATGTTCTGTGTCAAATAGCAGCACCACT 
AGTGGTGCTGCTATTTGACACAGAACATGTTTATTTACTC 
 
premiR-32 amplification primers 
premiR-32_for 
premiR-32_rev 
TGCATCTAGAATGATCATTGCTGAC 
CTGCTGAATTCATTGAAGTTTTGAACC 
Sequencing primer 
Rluc3end GTGCTGAAGAACGAGCAG 
 
Real-time PCR primers 
Real-time PCR primers (Human) 
ACTB_for_qpcr AAAAGCCACCCCACTTCTCT 
ACTB_rev_qpcr CTCAAGTTGGGGGACAAAAA 
DNAJB1_for_qpcr GCAGTCTTGATTCCCAGACC 
DNAJB1_rev_qpcr GCTGGAACGAGAGGTATTGC 
ATXN3_for_qpcr CCGCAGGGCTATTCAGCTAA 
 
ATXN3_rev_qpcr CTCGTCTCTTCCGAAGCTCTTC 
 
GAPDH_for_qpcr CCACCCATGGCAAATTCC 
 
GAPDH_rev_qpcr TGGGATTTCCATTGATGACAAG 
 
MID1_for_qpcr CTGCCAGGTCTGGTGTCATG 
 
MID1_rev_qpcr AATCAGGCTTAGGGCCCTTCT 
Real-time PCR primers (Mouse) 
GAPDH_MM_For GCACAGTCAAGGCCGAGAAT 
GAPDH_MM_Rev GCCTTCTCCATGGTGGTGAA 
 
Dnajb1_MM_For2 AGGCTCTCTGTGGTTGCACT 
Dnajb1_MM_Rev2 TTCTGGATGAGACGGGAATC 
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2.1.7 miRNA mimics/siRNAs 
miRNA mimics Sequence 
hsa-miR-32 UAUUGCACAUUACUAAGUUGCA 
hsa-miR-181c AACAUUCAACCUGUCGGUGAGU 
hsa-miR-216a-5p UAAUCUCAGCUGGCAACUGUGA 
hsa-miR-374a-5p UUAUAAUACAACCUGAUAAGUG 
hsa-miR-542a-3p UGUGACAGAUUGAUAACUGAAA 
hsa-miR-370 GCCUGCUGGGGUGGAACCUGGU 
hsa-miR-543 AAACAUUCGCGGUGCACUUCUU 
control siRNA1 AATTCTCCGAACGTGTCACGT 
 
 
 
2.1.8 Antibodies 
 
Primary antibodies 
The abbreviations IB and IF stand for immunoblotting and immunofluorescence 
respectively and denote the application for which a specific antibody dilution was used.  
 
Name Source Dilution Company/Provider 
GAPDH Rabbit monoclonal IB: 1: 5000 Cell Signalling  
(2118L/2118S) 
DNAJB1 (Hsp40) Rabbit polyclonal IB: 1:5000 
IF: 1:300 
Enzo (ADI-SPA-
400) 
α-Tubulin Rat monoclonal IB: 1:5000 Serotec (MCA77G) 
c-Myc Mouse monoclonal IF: 1:300 Clontech (631206) 
ATXN3, clone 1H9 Mouse monoclonal IB: 1: 1000 Millipore 
(MAB5360) 
MID1 Rabbit polyclonal IB: 1:200 AG Krauss (DZNE, 
Bonn) 
ATXN3 (no.986) Rabbit polyclonal IB: 1:5000 Dr. Peter Breuer 
(Uniklinik Bonn) 
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 Secondary antibodies 
Name Dilution Company 
goat α rat igG-HRP conjugated IB: 1:3000 SantaCruz biotech (SC-2303) 
goat α mouse igG-HRP conjugated IB: 1:3000 Dianova (115-035-003) 
donkey α rabbit igG-HRP 
conjugated 
IB: 1:3000 Amersham (NA-9340) 
goat α mouse igG-Cy3 conjugated IF: 1: 1000 Dianova (715-166-151) 
goat α rabbit igG-Alexa Fluor 647 
conjugated 
IF: 1: 1000 Invitrogen (A 21244) 
 
2.1.9 Cell lines 
Cell line Source 
Hela Human cervical cancer 
HEK-T 293 Human embryonic kidney 
iPSC-derived neurons Neurons differentiated from iPSCs derived from 
control and SCA3 patient fibroblasts 
 
2.1.10 Cell and bacterial culture media 
Hela/HEK-T 293 culture medium 
DMEM+GlutaMAX 89% 
FBS 10% 
Penicillin (10,000 U/mL) + 
Streptomycin (10,000 µg/mL) 
1% 
 
Cell freezing medium 
DMEM+GlutaMAX 50% 
FBS 40% 
DMSO 10% 
 
Luria Broth and Luria Broth agar 
LB powder 20.6 g (per 1 litre of H2O) 
Agar (optional; used for plates) 15 g 
Autoclave 15 min at 121°C 
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Section 2.2 Methods 
2.2.1 Prediction of miRNA target sites 
Predictions for miRNA binding sites on 3’UTRs of ATXN3, MID1, DNAJB1 were done 
using the following two target prediction tools: 
1. TargetScan Human prediction database Release 6.2, June 2012 (www.targetscan.org) 
(Lewis et al, 2005)  
TargetScan considers several parameters contributing to mRNA targeting by stable 
mRNA-miRNA binding at specific sites such as: 
 Type of Watson-Crick (WC) match at the seed region of the miRNA (8mer, 7mer-
m8, 7mer-A1) (Grimson et al, 2007) 
 WC match at the 3’ end of the miRNA (Friedman et al, 2009; Grimson et al, 
2007) 
 Number of A and U nucleotides flanking the miRNA sequence (Grimson et al, 
2007) 
 Position of the target site within the entire mRNA (Grimson et al, 2007) 
 Free energy of the mRNA-miRNA duplex (Garcia et al, 2011) 
 Abundance of mRNAs with target sites for a particular miRNA (Garcia et al, 
2011) 
 Preferential evolutionary conservation of the specific target site to maintain 
miRNA targeting (Lewis et al, 2005) 
For the TargetScan predictions, the longest 3’UTR of the respective mRNAs was 
considered. miRNAs belonging to miRNA families either conserved only in mammals or 
conserved broadly in vertebrates were considered for the predictions. 
 
2. miRanda-miRSVR database, August 2010 Release (www.mirna.org) (Betel et al, 2010; 
Betel et al, 2008)  
For the miRanda-miRSVR predictions, the species was defined (Homo sapiens) and the 
predictions for the suggested transcript were considered along with miRNA binding 
alignment details.  
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2.2.2 Molecular cloning 
Cloning of 3’UTR sequence into the luciferase reporter vector 
Sequence of the 3’ UTRs of ATXN3, MID1, DNAJB1 containing the miRNA binding 
sites of interest were cloned downstream of the Renilla luciferase gene in the psiCHECK-2 
vector. Figure 2.1 shows as an example the 3’UTR of ATXN3 cloned into the 
pSICHECK-2 vector.  
 
Figure 2.1: Map of the psiCHECK-2 reporter vector with partial sequence of ATXN3 
3’UTR cloned downstream of the Renilla luciferase gene. The Firefly luciferase also 
present on the vector is used for signal normalization. 
 
ATXN3, MID1 and DNAJB1 3’UTR fragments were PCR amplified prior to being cloned 
into the psiCHECK-2 luciferase reporter vector according to the procedure as follows. 
Forward and reverse primers to PCR amplify the 3’UTR fragments were designed 
containing digestion sites for the restriction enzymes xho1 and not1 respectively (table 
2.1.6). The amplification reaction mix and the reaction conditions are shown in the table 
below. Genomic DNA extracted from Hela cells was used as template for the PCR 
reaction. All reagent additions were done on ice. 
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Reagent Volume (µL) Final conc. 
Gotaq Green master mix (2x) 12.5 µL 1x 
Forward primer (10 µM) 1 µL 400 nM 
Reverse primer (10 µM) 1 µL 400 nM 
DNA template (100ng/µL) 1 µL 4 ng/µL 
DMSO 0.5 µL 2% 
ddH2O 9 µL  
Cycling conditions 
3 min 95°C; 34x(30 sec 95°C, 30 sec 58°C, 2 min 72°C); 10 min 72°C 
 
Following the PCR reaction, the molecular weight of the PCR product was analysed by 
agarose gel electrophoresis of 3 µL aliquot of the PCR product using a gel containing 1% 
agarose in 1x TAE. The PCR product was purified using the QIAquick PCR purification 
kit according to the manufacturer’s instructions. The concentration of the purified PCR 
product was measured using the Nanodrop spectrometer. Digestion reactions to digest the 
PCR product and psiCHECK-2 vector by xho1 and not1 restriction enzymes were 
prepared as shown in the table below. All reagent additions for the restriction digestion 
reaction were done on ice. 
Reagent Volume (µL) Final conc. 
10x NEB buffer 3 5 1x 
xho1 (20 U/µL) 1 0.4U/µL 
not1(10 U/µL) 1 0.4U/µL 
100x BSA 0.5 1x 
Purified DNA 
 (PCR product/psiCHECK-2 
vector) (50 ng/µL) 
20 1µg/50µL 
ddH2O 22.5  
Double digestion mix incubated at 37°C for 4 hours 
  
The digested psiCHECK-2 vector was separated from the undigested vector by agarose gel 
electrophoresis of the digestion mix (1% agar in 1x TAE). The gel piece carrying the 
digested vector was cut out with a scalpel and the vector DNA extracted using the 
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QIAquick Gel extraction kit using the manufacturer’s instructions. Meanwhile the double 
digested PCR product was purified using the QIAquick PCR purification kit according to 
the manufacturer’s instructions. The DNA concentration of the digested, purified PCR 
product and psiCHECK-2 vector was measured using the Nanodrop spectrometer.  
A ligation reaction to ligate the double digested insert (PCR product) into the double 
digested psiCHECK-2 vector was setup with insert:vector molar ratio of 3:1 as shown in 
the table below.  
Reagent Volume (µL) Final conc. 
10x T4 DNA ligase buffer 2 1x 
Insert (20ng/µL) 3.5 75ng/20µL 
Vector (25ng/µL) 3 70ng/20µL 
ddH2O 10.5  
T4 DNA ligase (400U/µL) 1 20U/µL 
Ligation mixture incubated at 16°C for 16 hours 
 
Bacterial transformation of E.coli Top10 with ligation mixture  
A 50µL aliquot of the competent cells was transformed with 2µL of the ligation mixture 
following which cells were placed on ice for 20 minutes, given a heat shock at 42°C for 1 
minute, further kept on ice for 30 minutes, 250 µL of LB medium was added and the cells 
were incubated at 37°C for 45 minutes on bench top shaker. 50 µL and 250 µL aliquots of 
the cell suspension were plated onto two LB agar plates with 100 µg/mL Ampicillin. 
Plates were incubated for 16 hours at 37°C.  
Following incubation, 5-10 colonies appearing on the plates were picked and used to 
inoculate 500 µL aliquots of LB medium with 100 µg/mL Ampicillin in microcentrifuge 
tubes. Following incubation at 37°C for 16 hours on the shaker, the aliquots which showed 
visible signs of bacterial growth (medium getting turbid) were further utilized to extract 
plasmid DNA using the GenElute Five minute plasmid miniprep kit (Sigma Life Science).        
Plasmid DNA extracted was double digested with xho1 and not1 in order to verify the 
insertion of the required fragment in the vector. The digestion reaction was set up similar 
to the one in the table above but with smaller total reaction volume (total reaction volume 
being 15µL) with the volumes of the reagents reduced proportionally. The digested 
Materials and Methods     
31 
 
plasmid DNA was run on 1% agarose gel to separate the cleaved insert from the vector. 
Up to three clones carrying the insert as suggested by agarose gel electrophoresis were 
sequenced using the reverse primer used for PCR amplification and the Rluc3’end primer. 
The sequencing was done by GATC Biotech and the sequences were analysed using the 
4Peaks software. 
Based on the sequencing results a bacterial clone carrying the plasmid with the desired 
insert sequence was chosen for generation of large amounts of the plasmid to be used for 
transfection experiments of mammalian cells. For this, 100 mL of LB with 100µg/mL of 
Ampicillin was inoculated with an aliquot of the bacterial clone. The inoculum was 
incubated in a shaker incubator at 37°C for 16 hours at 150 rpm. Plasmid DNA was 
extracted from the bacterial suspension using the Jetstar 2.0 plasmid maxiprep kit. The 
purified plasmid DNA was eluted in 1 mL of Nuclease free H2O and the DNA 
concentration measured using the Nanodrop spectrometer. 
The presence of the insert and its sequence were verified once more by repeating the xho1, 
not1 double digest and sequencing as described above.    
 
Site directed mutagenesis of miRNA binding sites in 3’UTR sequences 
Complementary forward and reverse primers were designed to include the intended base 
pair substitution mutations in the middle of the primer sequence with flanking regions of 
unmodified sequence on both sides (table 2.1.6). Using the psiCHECK-2 vector with the 
wild type 3’UTR of ATXN3, MID1 or DNAJB1 as the DNA template, the vector carrying 
the mutations in the insert was PCR amplified using the high fidelity Pfu ultra II DNA 
polymerase as per the reaction mix in the table below. 
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Reagent Volume (µL) Final conc. 
10x Pfu ultra II HF reaction buffer 5 1x 
Forward primer (10 µM) 1 200 nM 
Reverse primer (10 µM) 1 200 nM 
DNA template (50 ng/µL) 1 1ng/µL 
dNTP mix (40 mM) 1 800 µM 
DMSO 3 6% 
ddH2O 37  
Pfu ultra II HF polymerase (2.5U/µL) 1 0.05U/µL 
Cycling conditions 
1 min 95°C; 18x (50 sec 95°C, 50 sec 60°C, 8 min 68°C); 7 min 68°C  
1 µL of Dpn I restriction enzyme (10U/µL) was added to the PCR product and the product 
was incubated at 37°C for 2 hours to digest the non-mutated vector. 5 µL of the digested 
product was separated on 1% agarose gel. Presence of a band at the expected molecular 
weight confirmed the PCR amplification of the vector with the mutant insert. The 
subsequent procedure including bacterial transformation, plasmid DNA extraction, 
sequencing was the same as described before.   
 
Cloning of premiR-32 into the pMIRNA1 vector 
pMIRNA1 vector containing premiR-181c was purchased. The miR-32 stem loop 
sequence alongwith 200 nt on either flanks was cloned into the pMIRNA1 vector after 
cleaving out the premiR-181c sequence. A representation of this is shown in Figure 2.2. 
In order to clone premiR-32 into the vector, the premiR-181c sequence was cleaved out 
using sequential digestion with Xba1 and EcoRI. Cloning primers to amplify premiR-32 
were designed containing digestion sites for Xba1 and EcoRI.  PCR amplification reaction 
was set up according to the table below. 
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Reagent Volume (µL) Final conc. 
Gotaq Green master mix (2x) 12.5 µL 1x 
Forward primer (10 µM) 1 µL 400 nM 
Reverse primer (10 µM) 1 µL 400 nM 
DNA template (100ng/µL) 1 µL 4 ng/µL 
DMSO 0.5 µL 2% 
ddH2O 9 µL  
Cycling conditions 
3 min 95°C; 34x(30 sec 95°C, 30 sec 60°C, 2 min 72°C); 10 min 72°C 
 
The molecular weight of the amplified PCR product was verified using 1% agarose gel 
electrophoresis. The product was purified using QIAquick PCR purification kit. The PCR 
product as well as pMIRNA1 vector were digested by xba1, purified and then digested by 
EcoRI as per the table below  
Reagent Volume (µL) Final conc. 
10x NEB buffer 4/EcoRI buffer 5 1x 
xba1 (20 U/µL)/EcoRI (20 U/ µL) 1 0.4U/µL 
100x BSA 0.5 1x 
Purified DNA 
 (PCR product/pMIRNA1 vector)    
(50 ng/µL) 
20 1µg/50µL 
ddH2O 22.5  
Digestion mix incubated at 37°C for 2 hours for each digestion step 
 
The digested vector as well as the PCR product were gel extracted using the QIAquick gel 
extraction kit. The ligation of the vector and the insert, bacterial transformation and the 
Maxiprep extraction were as described for the cloning procedure for inserts in the 
psiCHECK-2 vectors.  
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Figure 2.2: The pMIRNA1 vector was used to over express miR-32 and miR-181c.  
Precursor sequence of miR-32 (70 nt, shown in red) along with flanking sequences on both 
sides (200 nt, shown in blue) was cloned in the pMIRNA1 vector.  
 
2.2.3 Cell culture methods 
Maintenance of human cancer cell lines 
Details regarding the origin of Hela and HEK T-293 cells used are given in table 2.1.9. 
The cells were cultured in DMEM supplemented with 10% FBS, 100 U/mL of Penicillin, 
100 µg/mL of Streptomycin. Cells were grown in 75/150 cm
2
 tissue culture flasks at 37°C 
and 5% CO2. For subculturing the cells were washed 1x in PBS and dislodged from the 
flask surface by incubation with Trypsin-EDTA for 5 minutes. The trypsinized cells were 
resuspended in complete medium. The cells were subcultured at a dilution of 1:10-1:20 
depending on the cell line three times a week. The subculturing was done in sterile 
conditions under the Laminar airflow hood. 
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Counting of cells 
Cells were trypsinized and resuspended in complete medium. 25 µL of the cell suspension 
was diluted in 10 mL of CASY ton solution in a CASY tube. The capillary of the CASY 
cell analysis system was washed 1x in CASY ton. The CASY tube carrying the cell 
suspension was placed under the capillary and the cells counted choosing the appropriate 
program (default programs for Hela and HEK T-293 cells were used). Cell count per mL 
was calculated by considering the dilution factor (by multiplying the displayed cell count 
by 4).  
 
Freezing of cells 
Cells grown to about 80% confluency in tissue culture flasks were trypsinized, suspended 
in complete medium and transferred to 50 mL centrifuge tube. Cells were counted to 
determine the cell count per mL and centrifuged at 1500 rpm for 5 minutes in order to 
pellet them. The supernatant was removed and the cells were resuspended in ice cool 
freezing medium (50% DMEM, 40% FBS, 10% DMSO). The volume of freezing medium 
for resuspension was such that the cell count would be 2 million cells per mL of freezing 
medium. 1 mL aliquots of the resuspended cells were prepared in cryo tubes. The cryo 
tubes were immediately transferred to a pre cooled cell freezing container containing 
isopropyl alcohol and transferred to -80°C freezer. After storage -80°C for 24 hours the 
cells were transferred to the liquid nitrogen tank for long term storage. 
 
Thawing of cells 
Cells frozen in liquid nitrogen were thawed by immersing the cryo tube in water bath at 
37°C till the ice crystals inside the cryo tube had melted. Cells from each cryo tube were 
transferred to 150 cm
2
 tissue culture flask containing complete medium. Cells were 
incubated under appropriate culture conditions (37°C, 5% CO2) for 24 hours after which 
the medium was replaced with fresh complete medium.  
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Transfection of miRNA mimics and control siRNAs 
Cells were transfected with miRNA mimics and control siRNAs using the method of 
reverse transfection, in which the transfection mix was added to the cell culture plate first 
and cells were then seeded into the mix. Two separate solutions, solution A containing the 
miRNA mimics or control siRNAs and solution B containing the transfection reagent 
Lipofectamine 2000 were prepared separately in microcentrifuge tubes. For the miRNA 
mimics, each mimic was transfected at a final amount of 30 picomoles per well of the 12-
well plate. The control siRNA amounts were adjusted according to the number of miRNA 
mimics transfected together such that the total RNA amount was equal in the control/test 
wells. Therefore, 60 picomoles of control siRNA were used in the experiment where two 
miRNAs transfected, 90 picomoles of control siRNA for experiment where three miRNAs 
were transfected. The table below shows the transfection mix preparation for experiment 
with two miRNA mimics. 
 Volume per one well of 12-well plate (µL) 
Solution A Opti-MEM 47 
miRNA1 stock (20 µM) 
miRNA2 stock (20 µM) 
1.5 
1.5 
Solution B Opti-MEM 49 
Lipofectamine 2000 1 
Solution A was added dropwise to solution B to make up the transfection mix. The 
transfection mix was incubated on the benchtop for 20 minutes.  The transfection mix was 
then added to each well of a 12-well plate. While the transfection mix was incubating, the 
cells were trypsinized, counted and a cell suspension with a cell count of 100,000 cells/mL 
was prepared in complete medium. 1 mL of the cell suspension was added dropwise to 
each well of the 12-well plate already containing the transfection mix. The cells were 
grown for 48 hours under appropriate culture conditions (37°C, 5% CO2).   
 
Transfection of Luciferase reporter vectors  
Cells were transfected with Luciferase reporter constructs using the method of forward 
transfection, in which the cells were seeded in plates prior to transfection. In this 
experiment, the cells were seeded in 12-well tissue culture plates at a density of 100,000 
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cells/well 24 hours prior to transfection. On the day of transfection, two separate solutions, 
solution A containing the luciferase reporter constructs and solution B containing the 
transfection reagent Lipofectamine 2000 were prepared separately in microcentrifuge 
tubes as per the calculations in the table below. 
 Volume per one well of 12-well plate (µL) 
Solution A Opti-MEM 96 
Luciferase reporter 
vector (100 ng/µL) 
4 
Solution B Opti-MEM 98 
Lipofectamine 2000 2 
 
Solution A was added dropwise to solution B to make up the transfection mix. The 
transfection mix was incubated on the benchtop for 20 minutes and added to each well of 
the 12-well plate containing the seeded cells. The cells were grown for 48 hours under 
appropriate culture conditions (37°C, 5% CO2).   
 
Transfection of pMIRNA1 vector containing precursor miRNA sequence inserts 
Transfection of Hela cells with pMIRNA1 vectors containing precursor miRNA sequence 
inserts was carried out similar to the transfection of luciferase constructs in terms of the 
cell density, transfection time, incubation conditions. The transfection mix was prepared 
as shown in the table below. 
 Volume per one well of 12-well plate 
(µL) 
Solution A Opti-MEM 96 
pMIRNA vector (500 
ng/µL) 
4 
Solution B Opti-MEM 98 
Lipofectamine 2000 2 
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 Co-transfection of miRNA mimics and c-terminal ATXN3 contruct 
Cells were co-transfected with miRNA mimics/control siRNAs and c-terminal ATXN3 
constructs using the method of forward transfection. In this experiment, the cells were 
seeded in lab-Tek II chamber slides at a density of 40,000 cells/chamber, 24 hours prior to 
transfection. On the day of transfection, two separate solutions, solution A containing the 
miRNA mimics/control siRNAs and the c-terminal ATXN3 construct and solution B 
containing the transfection reagent Lipofectamine 2000 were prepared separately in 
microcentrifuge tubes. 7.5 picomoles of two miRNAs were transfected together. 
Therefore, the control siRNA amount transfected in the control wells was 15 picomoles. 
The transfection mix was prepared as shown in the table below. 
 Volume per one chamber of a slide 
(µL) 
Solution A Opti-MEM 10.5 
miRNA stock (20 µM) 0.375 
0.375 
c-terminal ATXN3 contruct 
 (200 ng/µL) 
1.25 
Solution B Opti-MEM 11.75 
Lipofectamine 2000 0.75 
Solution A was added dropwise to solution B to make up the transfection mix. The 
transfection mix was incubated on the benchtop for 20 minutes and added to each well of 
the 12-well plate containing the seeded cells. The cells were grown for 48 hours under 
appropriate culture conditions (37°C, 5% CO2).   
 
Harvesting and pelleting of cells 
Cell pellets were prepared for RNA or protein extraction. Cells were trypsinized, 
resuspended in complete medium and transferred to microcentrifuge tubes. The cells were 
centrifuged at 1500 rpm for 10 minutes at 4°C. The cell pellet was washed 1x with ice 
cold PBS and the centrifugation step above was repeated. The PBS was aspirated and the 
cell pellets were either lysed in appropriate buffers for RNA/protein extraction or stored at 
-20°C. 
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Cells transfected with luciferase reporter vectors and used for luciferase assays were 
washed 1x in PBS in the tissue culture plate followed by addition of 100 µL of passive 
lysis buffer to each well of 12-well plate. The plates were incubated on shaker at room 
temperature for 20 minutes followed by transfer of the cell lysate into microcentrifuge 
tubes. The cell lysates were either used directly for luciferase assays or stored at -20°C. 
 
Harvesting of iPSC derived neurons  
Control and SCA3 iPSC derived neurons grown in 6 cm dishes were washed three times in 
balanced salt solution (BSS), gently dislodged from the dish surface with a cell scrapper 
and transferred to a 50 mL centrifuge tube. The cells were pelleted by centrifugation at 
1500 rpm for 10 minutes. The BSS was aspirated, the pellets were flash frozen in liquid 
nitrogen and stored at -80°C.   
 
2.2.4 Molecular biology methods 
Total RNA quantification 
Total RNA extraction including small RNAs from iPSC derived neurons was conducted 
using the miRVana miRNA isolation kit according to the manufacturer’s instructions. 
Total RNA extraction from human cell lines, mouse brain samples was conducted using 
the RNeasy plus mini kit according to the manufacturer’s instructions. In both cases, the 
total RNA was eluted in nuclease-free H2O preheated to 70°C. 
 
Reverse transcription 
Reverse transcription was carried out using the Taqman reverse transcription kit according 
the manufacturer’s instructions. The reverse transcription reaction was set up with a final 
volume of 50 µL. 1 µg of total RNA was used as template, with random hexamers used as 
primers. The reaction mixture and the cycling conditions are shown in the table below. 
 
Materials and Methods     
40 
 
Reagent Volume (µL) Final conc. 
10x Reverse transcriptase buffer 5 1x 
MgCl2 (25 mM) 11 5.5 mM 
dNTPs (10 mM) 10 2 mM 
Random hexamers (50 µM) 2.5 2.5 µM 
RNase Inhibitor (20 U/µL) 1 0.4 U/µL 
Multiscribe reverse transcriptase 
(50 U/µL) 
2.5 1 U/µL 
RNA template (500 ng/µL) 2 20 ng/µL 
Nuclease free H2O 16  
Cycling conditions 
10 min 25°C; 30 min 37°C; 5 min 95°C; hold 4°C 
 
SYBR Green Real-time PCR 
SYBR Green dye based real-time PCR amplification was done in the 7900HT Fast Real-
time PCR cycler in 384 well plates. SYBR Green PCR master mix (Life technologies) 
containing SYBR Green1 dye, Amplitaq DNA polymerase and dNTPs with dUTP was 
used for amplification. cDNA produced by reverse transcription of RNA samples was 
diluted 1:10 to be used as template for the real-time PCR. Primers used in the real-time 
PCR have been listed in table 2.1.6. In each experiment, serial dilutions of one of the 
samples (usually one of the controls) were prepared to serve as reference for plotting of a 
standard curve plot for cDNA quantification. The PCR mix in each well and the cycling 
conditions were as described in the table below. All samples were loaded in triplicates. A 
dissociation stage was added at the end of each amplification cycle to check for 
amplification of multiple products. Following the amplification, wells flagged for errors in 
the signal were omitted from the calculations. Data was exported to MS Excel for analysis. 
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Reagent Volume (µL) 
SYBR Green PCR master mix (2x) 10 
Forward primer (10 µM) 1.5 
Reverse primer (10 µM) 1.5 
cDNA (1:10 diluted) 7 
Cycling Conditions 
2 min 94°C; 40x (15 sec 94°C, 1 min 60°C) 
 
Protein quantification 
Total protein in samples was quantified using the Qubit fluorometer and Qubit Protein 
assay kit according to manufacturer’s instructions. Prior to quantification, the samples 
were homogenized by pipetting gently.  
 
SDS PAGE 
Protein separation on the basis of molecular weight was carried out according to the 
method described by Shapiro and Laemmli (Laemmli, 1970; Shapiro et al, 1967). The 
SDS polyacrylamide gel was prepared using two glass plates separated by spacers with a 
thickness of 1.5 mm placed inside a casting chamber. For separation of the proteins, a 
‘running gel’ containing 10% acrylamide/bisacrylamide was prepared (formula given in 
table below) and poured to cover around 70% of the space between the glass plates. 
Isopropyl alcohol was poured to cover up the rest of the space between the glass plates till 
the running gel polymerized. Upon gel polymerization, the isopropyl alcohol was poured 
off by inverting the glass plates and the space was filled by pouring in the ‘stacking gel’ 
containing 5% acrylamide/bisacrylamide. A plastic comb containing 10/15 teeth was 
placed on top of the stacking gel to prepare sample wells. Upon polymerization of the 
stacking gel, the comb was removed and the sample wells formed were washed with 
electrophoresis buffer to remove any gel residue. The gel within the glass plates was 
transferred to the gel electrophoresis chamber and the chamber was filled with 
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electrophoresis buffer to an appropriate level as denoted on the chamber. The samples 
were loaded onto the sample wells, with one well reserved for the protein molecular 
weight ladder. Protein separation by electrophoresis was carried out by keeping the 
voltage constant at 100V. The electrophoresis was terminated once the visible migration 
border of the sample loading dye had passed out of the gel.   
Reagent Volume (mL) for a total of 10 mL 
 Running gel 
(10% 
acrylamide/bisacrylamide) 
Stacking gel 
(5% 
acrylamide/bisacrylamide) 
H2O 4 6.8 
30% Acrylamide mix 3.3 1.7 
1.5 M Tris (pH 8.8) 2.5 1.25 
10% SDS 0.1 0.1 
10% Ammonium 
persulfate 
0.1 0.1 
TEMED 0.004 0.01 
 
Immunoblotting 
The transfer of proteins from SDS gels to membranes is based on the technique described 
by Renart and Towbin (Renart et al, 1979; Towbin et al, 1979). Following electrophoretic 
separation of the proteins, the gel was removed from the glass plates and incubated in 1x 
blotting buffer for 10 minutes. Meanwhile, PVDF membrane of appropriate size was 
immersed in 100% methanol, washed in distilled H2O and immersed in 1x blotting buffer. 
In the semi dry blotting apparatus used, a Whatman paper of appropriate size soaked in 1x 
blotting buffer was placed followed by the PVDF membrane, the gel and finally another 
Whatman paper soaked in 1x blotting buffer. The lid containing other electrode of the 
apparatus was placed on top and the immunoblotting was carried out for 40 minutes at 
20V. The molecular weight ladder bands were marked using a pen to serve as reference 
marks during immunostaining. 
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Immunostaining 
The PVDF membrane with the transferred proteins was blocked in the blocking solution 
(3% BSA in TBST) for 1 hour at room temperature. The membrane was incubated with a 
solution containing the primary antibody at appropriate dilution (see table 2.1.8 for 
antibody dilutions) in blocking buffer for 12-15 hours at 4°C. The membrane was washed 
3x in TBST, followed by incubation with secondary antibody diluted in TBST for 1 hour 
at room temperature. Following incubation with the secondary antibody the membrane 
was again washed 3x in TBST. The developing solution was prepared as described in 
section 2.1.5. The washed membrane was briefly incubated in the developing solution 
containing substrate for the horse radish peroxidase enzyme. The membrane was then 
placed between plastic sheets and placed inside the Stella immunoblot imaging system. 
Images were taken at intervals ranging from 5 seconds to 10 minutes. Signals from the 
blots were quantified using AIDA imaging software.         
 
Immunocytochemistry 
Cells grown in Lab-Tek II chamber slides were washed once in PBS and fixated by 
incubation with 200 µL of 4% PFA in PBS for 15 minutes at room temperature. Following 
the fixation, the cells were washed thrice in PBS. The cells were then permeabilized by 
incubation with 200 µL of 0.5% Triton-X in PBS for 10 minutes at room temperature. The 
cells were again washed thrice in PBS and incubated with blocking solution, i.e. 200 µL of 
0.5% BSA in PBS for 20 minutes at room temperature. Following blocking, the cells were 
incubated in 150 µL of blocking solution containing appropriate dilutions (table 2.1.8) of 
one or two primary antibodies for 16 hours at 4°C. The cells were again washed thrice in 
PBS and incubated with 150 µL of PBS containing the secondary antibodies for 30 
minutes at room temperature in dark. Following incubation with the secondary antibody 
solution, the cells were washed thrice in PBS, the chamber walls were removed and 
Fluoroshield mounting medium containing DAPI was applied drop wise to the samples. 
Coverslips were gently placed over the mounted samples and the sides were sealed using a 
suitable sealant. Slides were directly used for sample visualization using the Laser 
scanning microscope, or were stored in the dark at 4°C.  
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Luciferase assay 
Lysates to be used for luciferase assay were diluted in H2O to attain a concentration of 1 
μg/μL. 10 μg of the protein lysate was pipetted into each well of a 96-well white plate. 
Each sample was pipetted in triplicate, for both the renilla and firefly luciferase 
measurements. Substrates for firefly and renilla luciferase were prepared as per the recipe 
given in section 2.1.5. The luciferase assay was conducted in Envision plate reader (Perkin 
Elmer). The reader was programmed to inject 40 μL renilla and firefly substrates in each 
well and measure luminescence signal following a lag of 2 seconds. Signal values were 
exported to and analysed in MS Excel.  
 
2.2.5 Microscopy and image analysis 
Confocal optical images of immunostained cells were taken using the Zeiss LSM 700 
microscope with a 20x air objective. Images were acquired using the Zen 2009 software 
through tilescans of multiple replicate chambers on the slide with identical transfection 
conditions. Image analysis to count the number of cells with aggregates was done using an 
algorithm setup by Dr. Möhl (Data and Image Analysis facility, DZNE Bonn).    
 
2.2.6 Mouse hindbrain isolation  
The maintenance and work with the B6.SCA3-YAC-84Q mice was conducted according 
to relevant national authority guidelines. 26 week old control and transgenic mice were 
sacrificed and the brain dissected to separate the hindbrain including the cerebellum, pons 
and the brain stem. The hindbrain was flash frozen in liquid nitrogen and broken up using 
a mortar and a pestle.  
Total RNA was extracted from the pulverized hindbrain using the RNEasy plus mini kit. 
RNA was quantified using the Nanodrop spectrometer. cDNA extraction and SYBR Green 
real-time PCR was done according to the procedure described before. Protein was 
extracted by homogenizing the pulverized hindbrain samples in SDS PAGE sample buffer, 
sonication and boiling at 95°C for 10 minutes.  
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2.2.7 Gene and miRNA expression profiling and analysis 
Gene and miRNA expression profiling by RNA-seq 
The gene expression and miRNA expression profiling was done using the technique of 
RNA-seq by the group of Dr. Stefan Bonn (Work group for computational analysis of 
biological networks, DZNE Göttingen) on an Illumina HiSeq2000TM with libraries 
prepared according to the Illumina TruSeq mRNA and small RNA protocols respectively.  
The FASTQ files generated for the gene expression profiling were used for analysis by the 
CLC Workbench (details below) in house. The analysis of the miRNA expression profile 
including steps such as trimming, sequence quality check, alignment of the sequences to 
small RNA transcript databases and differential small RNA analysis was conducted by the 
aforementioned group. 
 
Differential gene expression analysis by CLC genomics workbench 
The gene expression profile data was analysed using the CLC genomics workbench. RNA-
seq files for the gene expression profile were imported to the CLC server. The sequences 
were trimmed using default parameters to remove low quality sequences, ambiguous 
nucleotides and sequences below specific, defined length. The sequences were then 
assembled, i.e. they were aligned by comparing to reference sequences from GenBank, in 
order to make contiguous sequences. Default parameters were used for sequence 
assembly. The control and SCA3 patient samples were grouped into ‘control’ and ‘patient’ 
groups respectively. An experiment was then set up to analyse the differential expression 
of genes between the control and patient groups. Results were displayed including 
parameters such as mean expression values in the groups, fold changes in gene expression 
between the two groups with the p-values corrected for False Discovery Rate (FDR). The 
data was exported to MS Excel where it was sorted, filtered and arranged in lists which 
served as starting points for Gene Ontology analysis, pathway analysis.  
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Gene ontology and pathway analysis of dysregulated genes  
Gene Ontology analysis and Pathway analysis was conducted using the Toppfun tool from 
the Toppgene Suite (https://toppgene.cchmc.org/enrichment.jsp) (Chen et al, 2009). 
Default parameters for the correction, p-value cutoff were used. Lists were exported to MS 
Excel to be sorted.  
 
Protein interaction analysis 
Protein interaction analysis was conducted using the STRING database, ver 9.1 
(http://string-db.org) (Franceschini et al, 2013). The multiple names input option was used 
for gene list and the actions view was used for the graphic representation of the protein 
interaction analysis. 
 
Pathway analysis of dysregulated miRNAs 
miRNA pathway analysis was done using the MIRSYSTEM, May 2014 release (Lu et al, 
2012). The ‘miRNAs to targets’ tool was used to calculate the enrichment of the predicted 
miRNA targets into pathways via the ‘pathway ranking summary’ option in the tool. 
Results were exported to MS Excel for sorting, filtering.  
 
2.2.8 Software used 
4Peaks 
DNA sequences obtained from Sanger sequencing were analyzed using the 4Peaks 
software. The quality of the sequence was verified by analyzing the peaks representing the 
four nucleotides in the DNA sequence. 
 
AIDA image analyzer 
Immunoblot images were quantified using the AIDA image analysis software from 
Raytest. The areas containing signal bands from individual samples were selected and the 
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signal intensity measured. After subtraction of the background signal, the signal values 
were exported to MS Excel.  
 
GraphPad Prism version 6 
Statistical analysis and bar graph images were prepared using the Prism version 6 
software.  
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Chapter 3 Results  
 
3.1 miRNA targeting of ATXN3  
One of the main goals of this project was the identification of miRNAs able to target the 
ATXN3 mRNA by binding at specific sites on the 3’UTR leading to modulation of the 
ATXN3 protein expression. Therefore, the following steps were taken: 
 In silico prediction of miRNAs targeting the 3’UTR of ATXN3 mRNA . 
 Validation of the ability of the selected miRNAs to bind at specific sites on the 
3’UTR of ATXN3 mRNA. 
 Analysis of the miRNAs’ effect on endogenous ATXN3 mRNA and protein levels 
in human cell lines. 
 
  
3.1.1 In silico prediction of miRNAs targeting the 3’UTR of ATXN3 mRNA  
The 3’UTR of ATXN3 mRNA is 5904 nt long.  Several tools that enable miRNA target 
prediction are available, each with a different algorithm for predicting the strength of the 
miRNA-target mRNA binding. The TargetScan tool was primarily used for predictions. 
TargetScan considers several parameters contributing to mRNA targeting by stable 
mRNA-miRNA binding at specific sites as elaborated in the section of materials and 
methods (see 2.2.1). Based on these parameters, there are more than 40 miRNAs predicted 
to target ATXN3 3’UTR according to TargetScan. From amongst these, five miRNAs 
were chosen for validation experiments as given in table 3.1. Apart from TargetScan, the 
chosen miRNAs are also predicted to target ATXN3 3’UTR by miRanda-mirSVR, which 
is another widely used algorithm to predict miRNA target predictions.  
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miRNA TargetScan miRanda-miRSVR 
hsa-miR-9 ✗ ✗ 
hsa-miR-32 ✗ ✗ 
hsa-miR-125a-5p ✗ ✗ 
hsa-miR-181c ✗ ✗ 
hsa-miR-383 ✗ ✗ 
Table 3.1: miRNAs that are chosen for ATXN3 targeting experiments. These miRNAs 
are predicted to target the ATXN3 3’UTR by the tools TargetScan and miRanda-miRSVR. 
 
The details of the location of binding sites of the chosen miRNAs on the ATXN3 3’UTR 
as well as their seed match type are given in table 3.2. The locations of the binding sites of 
the selected miRNAs on the ATXN3 3’UTR are shown in figure 3.1. 
miRNA family Number of 
conserved target 
sites 
Location on the 
3’UTR sequence 
(from the 5’ end) 
Type of site 
hsa-miR-9 1 190-196 7mer 
hsa-miR-
32/25/92a/92b/363/367 
1 259-266 8mer 
hsa-miR-125a-
5p/125b 
1 1488-1494 7mer 
hsa-miR-
181a/181b/181c/181d 
3 a. 770-776 
b. 929-936 
c. 1381-1387 
a. 7mer 
b. 8mer 
c. 7mer 
hsa-miR-383 1 551-558 8mer 
Table 3.2: Binding site characteristics of the chosen miRNAs. Shown above is the 
number of binding sites of the miRNAs, their location on the ATXN3 3’UTR and the 
number of complementary nucleotides in each site. 
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Figure 3.1: A pictorial representation of the ATXN3 3’UTR with the locations of the 
binding sites of the selected miRNAs. The binding sites of the miRNAs selected lie 
within the initial 2000 nt of the ATXN3 3’UTR. 
 
3.1.2 Validation of the ability of the selected miRNAs to bind at specific sites on the 
3’UTR of ATXN3 mRNA 
In order to analyse the ability of miRNAs from the above families to target the ATXN3 
3’UTR at the specific binding sites, the initial 2000 nt sequence of the ATXN3 3’UTR 
was cloned into the luciferase reporter vector psiCHECK-2 downstream of the Renilla 
luciferase. The binding sites for the selected miRNAs were individually mutated by 
substitution of two nucleotides at the location corresponding to nucleotide 2 and 3 on the 
miRNA seed region. An example for the miR-32 binding site mutant is shown in figure 
3.2 (figures for the other miRNA mutants are shown in the appendix). In each miRNA 
binding site, the two bases at these locations were replaced by bases that would be unable 
to form a Watson-Crick base pairing with corresponding bases in the miRNA. The 
resulting mismatch prevents miRNA mediated targeting of the mutant ATXN3 3’UTR, 
which in turn prevents the degradation of the mRNA molecules which contain the Renilla 
luciferase sequence preceding the mutant ATXN3 3’UTR.   
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Figure 3.2: Representation of miR-32 binding to ATXN3 3’UTR at its predicted 
binding site. The binding of miR-32 to the wild type ATXN3 3’UTR is shown in (A), 
while the disruption to binding caused by mutations at two nucleotides in the miR-32 
binding site in ATXN3 3’UTR is shown in (B). 
 
Hela cells were transfected with either wild type or mutant ATXN3 3’UTR cloned 
downstream of the Renilla luciferase. The psiCHECK-2 vector also contains the sequence 
for Firefly luciferase. The cells were lysed 48 hours after transfections and Renilla and 
Firefly luciferase activity in the cell lysates was measured in a luciferase assay. The 
Firefly luciferase signal was used for normalization of the Renilla luciferase signal. As 
shown in figure 3.3, mutations of the miRNA binding sites on the ATXN3 3’UTR led to a 
significant increase in the ratio of the Renilla/Firefly luciferase for all the mutant 
constructs. The percentage increase in the signal ratio differed for each mutant from 20.5% 
for the miR-9 binding site mutant, to 117% for the mutant with binding site number 2 for 
miR-181c. This suggests that the endogenously expressed miRNAs from the Hela cells 
were able to target their predicted binding sites on ATXN3 3’UTR. Worth noting was the 
difference for the mutants of the two miR-181c binding sites with a 27.8% increase for 
binding site-1 and as mentioned above a 117% increase for binding site-2. This was 
expected, since the binding site-1 is a 7mer whereas the binding site-2 is an 8mer and 
therefore the binding of miR-181c to the ATXN3 3’UTR at binding site-2 is stronger, 
leading to enhanced targeting.   
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Figure 3.3: Mutations of miRNA binding sites of miR-9, 32, 125a-5p, miR-181c and 
miR-383 on ATXN3 3’UTR lead to increased Renilla/Firefly signal ratio. Binding 
sites of miRNAs on partial ATXN3 3’UTR sequence were mutated. Wild type and mutant 
constructs were transfected in Hela cells and Renilla, Firefly luciferase signals measured 
48 hours after transfection. Columns represent values +/- standard deviation. n = 27, P-
value = <0.0001 
 
3.1.3 Analysis of the miRNAs’ effect on endogenous ATXN3 mRNA and protein 
levels in human cell lines 
On the basis of the predicted thermodynamics of miRNA targeting of the ATXN3 mRNA, 
miR-32 and miR-181c have the strongest binding ability as compared to the other 
miRNAs considered. Hence these two miRNAs were chosen for further experiments 
involving analysis of effects of over-expression of these miRNAs on ATXN3 protein and 
mRNA levels. The overexpression of these two miRNAs was carried out in Hela cells 
using two strategies: 
 miRNA mimic oligonucleotides 
 miRNA precursor sequence containing expression vector 
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miRNA overexpression using miRNA mimic oligonucleotides  
One of the strategies to overexpress miR-32 and miR-181c was to transfect cells with 
mimic oligonucleotides of these two miRNAs. miRNA mimics are synthetically produced 
oligonucleotides that mimic the action of endogenously generated miRNAs.  Hela cells 
were transfected with miR-32 and miR-181c mimics or control siRNA with a scrambled 
sequence and lysed 48 hours after transfections. The effect of miR-32 and miR-181c on 
the amount of ATXN3 protein was analysed using immunoblotting whereas the effect on 
ATXN3 mRNA was analysed using SYBR Green real time PCR. As compared to cells 
transfected with a control siRNA, a significant decrease of up to 55% was observed in the 
amount of ATXN3 mRNA in Hela cells transfected with miR-32 and miR-181c mimics 
for 48 hours, as seen in figure 3.4. Corresponding to the downregulation in ATXN3 
mRNA levels, the levels of ATXN3 protein were also found to be decreased substantially 
upon miR-32 and miR-181c mimic transfection as seen in figure 3.5.  
 
Figure 3.4: Overexpression of miR-32 and miR-181c decreases ATXN3 mRNA level 
in Hela cells. miR-32 and miR-181c mimics were co-transfected in Hela cells. ATXN3 
and GAPDH mRNA levels (as loading control) were checked by SYBR Green real-time 
PCR 48 hours after transfection. Columns represent values +/- standard deviation. n = 4, 
P-value =  0.0004 
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Figure 3.5: Overexpression of miR-32 and miR-181c decreases ATXN3 protein levels 
in Hela cells. miR-32 and miR-181c mimics were cotransfected in Hela cells. The 
ATXN3 (A; upper panel) and GAPDH (A; lower panel) protein levels 48 hours post 
transfection were determined by immunoblotting using specific antibodies. As shown in 
(B) the ATXN3 protein levels were quantified based on the ratio of ATXN3 to the loading 
control GAPDH. Columns represent percentage value of ATXN3/GAPDH ratio.   
 
miRNA overexpression using and expression vector containing the miRNA precursor 
sequence 
The overexpression of miR-32 and miR-181c in Hela cells was also conducted using the 
strategy of cloning the sequence of miRNA precursor and flanking regions into the 
miRNA expression vector pMIRNA1. The precursor sequence of around 70 nt along with 
200 nt flanking regions on both sides is necessary for overexpression of the miRNAs. 
Upon transfection of this construct into Hela cells and expression of the precursor 
sequence, the protein Dicer involved in the RNAi machinery cleaves the precursor 
miRNAs to form the mature miRNAs, which associate with the miRISC complex to 
actively take part in post-transcriptional regulation of gene expression.  
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Hela cells were transfected with pMIRNA1 constructs expressing the precursor sequences 
of miR-32 and miR-181c.  As control, empty vector was transfected. The pMIRNA1 
vector includes the sequence for copGFP gene and hence GFP fluorescence was used as a 
visual marker to estimate the efficiency of cell transfection. A transfection efficiency of 
around 70-80% was achieved 48 hours after transfection.  
The cells were lysed 48 hours after transfection and ATXN3 protein levels from the cell 
lysates were analysed by immunoblotting. Transfected cells were also used for RNA 
extraction and SYBR Green real time PCR to analyse the ATXN3 mRNA levels.  
Upon overexpression of miR-32 and miR-181c in Hela cells, the ATXN3 mRNA levels 
were significantly downregulated as seen in Figure 3.6. In unison with this result, the 
immunoblotting of cell lysates with an antibody specific for ATXN3 showed a 
downregulation in the ATXN3 protein levels upon miR-32 and miR-181c overexpression 
as seen in figure 3.7.  
 
Figure 3.6: Precursor based overexpression of miR-32 and miR-181c leads to 
significant decrease in ATXN3 mRNA levels. Hela cells were transfected with 
pMIRNA1 vectors with precursors of both miRNAs. ATXN3 and GAPDH mRNA levels 
(as loading control) were checked by SYBR Green real-time PCR 48 hours after 
transfection. Columns represent values +/- standard deviation. n = 3, P-value = 0.002 
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Figure 3.7: Precursor based overexpression of miR-32 and miR-181c causes a 
decrease in ATXN3 protein levels. Hela cells were transfected with pMIRNA1 vectors 
with precursors of both miRNAs. ATXN3 (A; upper panel) and GAPDH (A; lower panel) 
protein levels 48 hours post transfection were determined by immunoblotting using 
specific antibodies. As shown in (B) the ATXN3 protein levels were quantified based on 
the ratio of ATXN3 to the loading control GAPDH.  
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3.2 miRNAs targeting Midline 1 (MID1) 
As described in the introduction, the MID1 protein has been shown to play an important 
role in the expression of polyQ expanded proteins through its action on the translation of 
mRNAs containing expanded CAG repeats. Hence, modulation of MID1 expression might 
affect the expression of polyQ protein and disease progress.  Deciphering which miRNAs 
might be able to target MID1 and modulate its expression was therefore one of the aims of 
this project. 
The strategy employed to discover the miRNAs targeting MID1 was similar to the one 
used for finding miRNAs targeting ATXN3.   
Hence the experiments were again divided into the following parts: 
 In silico prediction of miRNAs targeting the 3’UTR of MID1 mRNA 
 Validation of the ability of selected miRNAs to bind at specific sites on the 3’UTR 
of MID1 mRNA 
 Analysis of the miRNAs’ effect on endogenous MID1 mRNA and protein levels in 
human cell lines 
 
3.2.1 In silico prediction of miRNAs targeting the 3’UTR of MID1 mRNA 
The TargetScan miRNA target prediction tool was used to predict miRNAs, which 
potentially target the 3’UTR of MID1 mRNA. The MID1 mRNA is 4058 nt long. 
TargetScan predicted more than 60 miRNAs, which can potentially target the MID1 
3’UTR. Of these, three miRNAs were chosen for validation experiments (table 3.3). Apart 
from TargetScan, these miRNAs were also predicted to target MID1 3’UTR by another 
miRNA target prediction tool miRanda-miRSVR.  
miRNA TargetScan miRanda-miRSVR 
hsa-miR-216a-5p ✗ ✗ 
hsa-miR-374a-5p ✗ ✗ 
hsa-miR-542a-3p ✗ ✗ 
Table 3.3: miRNAs that are chosen for MID1 targeting experiments. These 3 miRNAs 
are predicted to target MID1 3’UTR by both TargetScan and miRanda-miRSVR. 
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The details regarding the predicted binding of these miRNAs on MID1 3’UTR, such as the 
number of conserved target sites, location of these target sites on 3’UTR, the type of site 
in terms of WC match to the miRNA seed sequence are given in table 3.4 below. hsa-
miR-374a belongs to the family of miRNAs, which also includes hsa-miR-374b. Hence, 
both miR-374a and miR-374b are predicted to bind at the same target site. The relative 
locations of the miRNA binding sites on the MID1 3’UTR is shown in figure 3.8.  
 
miRNA family Number of 
conserved target 
sites 
Location on the 
3’UTR sequence 
(from the 5’ end) 
Type of site 
hsa-miR-216a-5p 1 738-744 7mer 
hsa-miR-374a, 
374b 
1 1154-1161 8mer 
hsa-miR-542-3p 1 975-982 8mer 
Table 3.4: Binding site characteristics of miRNAs predicted to bind MID1 3’UTR. 
Shown above is the number of binding sites of the miRNAs, their location and the number 
of complementary nucleotides in each site. 
 
Figure 3.8: A graphical representation of the MID1 3’UTR with the locations of the 
binding sites of the three chosen miRNAs. All the chosen miRNA binding sites lie in the 
initial 1352 nucleotides of the MID1 3’UTR.  
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3.2.2 Validation of the ability of selected miRNAs to bind at specific sites on the 
3’UTR of MID1 mRNA 
To verify the ability of miR-216a-5p, miR-374a-5p and miR-542-3p to bind the MID1 
3’UTR at specific binding sites, the 1352 nucleotides of the MID1 3’UTR containing the 
predicted miRNA binding sites were cloned downstream of the Renilla luciferase in the 
luciferase reporter vector psiCHECK-2. The binding sites of the three miRNAs were 
mutated by two nucleotide base substitutions on the 3’UTR corresponding to position 2, 3 
of the miRNA seed region (example for miR-216a-5p in figure 3.9; figs for other two 
mutants in appendix). Wild type and mutant MID1 3’UTRs in psiCHECK-2 were 
transfected in Hela cells. Luciferase assays were conducted 48 hours after transfection. 
Signals from the Renilla luciferase were normalized by the Firefly luciferase signals. 
 
 
Figure 3.9: Representation of miR-216a-5p binding to MID1 3’UTR at its specific 
binding site. The binding of miR-216a-5p to the wild type MID1 3’UTR is shown in (A), 
while the disruption to the binding caused by mutations at two nucleotides in the miR-
216a-5p binding site on MID1 3’UTR is shown in (B).  
 
 
As seen in figure 3.10, compared to the wild type 3’UTR of MID1, a significant increase 
in the signal ratio of Renilla/Firefly was observed for the 3’UTR variants with mutations 
in the binding sites of miR-216a-5p, miR-374a-5p and miR-542-3p. This suggests that the 
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endogenously expressed miRNAs from the Hela cells were able to target their predicted 
binding sites on MID1 3’UTR. 
 
 
 
Figure 3.10: Mutations of miRNA binding sites on MID1 3’UTR lead to increased 
Renilla/Firefly signal ratio. Binding sites of miRNAs in partial MID1 3’UTR sequence 
were mutated. Wild type and mutant constructs were transfected in Hela cells and Renilla, 
Firefly luciferase signals measured 48 hours after transfection. Columns represent values 
+/- standard deviation. n = 6, P-value = < 0.0001   
 
3.2.3 Analysis of the miRNAs’ effect on endogenous MID1 mRNA and protein levels 
in human cell lines 
To analyse the effect of miR-216a-5p, miR-374a-5p and miR-542-3p on MID1 protein and 
mRNA levels, these miRNAs were over expressed in HEK-T 293 cells using their 
respective mimic oligonucleotides. The transfected HEK-T 293 cells were lysed 72 hours 
after transfections and MID1 protein levels were analysed by immunoblotting and mRNA 
levels were analysed by SYBR Green real time PCR.  
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As shown in figure 3.11, MID1 mRNA levels were downregulated in the cells transfected 
with the three miRNA mimics compared to controls. Correspondingly, MID1 protein 
levels were also reduced after transfection with the miRNA mimics as shown in figure 
3.12.  
 
Figure 3.11: Overexpression of miR-216a-5p, miR-374a-5p, miR-542-3p decreases 
MID1 mRNA levels in HEK-T 293 cells. miR-216a-5p, miR-374a-5p, miR-542-3p 
mimics were cotransfected in HEK-T 293 cells. MID1 and GAPDH mRNA levels (as 
loading control) were checked by SYBR Green real-time PCR 72 hours after the 
transfection. Columns represent values +/- standard deviation. n = 4, P-value = 0.0029  
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Figure 3.12: Overexpression of miR-216a-5p, miR-374a-5p, miR-542-3p decreases 
MID1 protein levels in HEK-T 293 cells. miR-216a-5p, miR-374a-5p, miR-542-3p 
mimics were cotransfected in HEK-T 293 cells. The MID1 (A; upper panel) and GAPDH 
(A; lower panel) protein levels 72 hours post transfection were determined by 
immunoblotting using specific antibodies. As shown in (B) the MID1 protein levels were 
quantified based on the ratio of MID1 to the loading control GAPDH. Columns represent 
percentage value of MID1/GAPDH ratio. 
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3.3 Analysis of differentially expressed miRNAs in iPSC-derived SCA3 
neurons  
 
3.3.1 Neurons derived from SCA3 iPSCs express wild type as well as the mutant 
ATXN3 allele 
To find miRNAs involved in SCA3 pathogenesis, neurons differentiated from Induced 
Pluripotent Stem Cells (iPSCs) from SCA3 patients and healthy controls were used. The 
iPSC generation, neuronal differentiation, characterization, and culture was conducted by 
collaborators in the Institute of Reconstructive Neurobiology, University of Bonn. In 
iPSC-derived SCA3 neurons, proteolytic cleavage of expanded ATXN3 by calpains 
induced by glutamate treatment of the neurons leads to formation of ATXN3 aggregates, 
which is a hallmark of SCA3 pathology (Koch et al, 2011). iPSC-derived neurons from 
three SCA3 patients and two healthy controls that had been differentiated for 8 weeks 
were used in this study. The details regarding the age, sex, repeat length, age of onset of 
the individuals are given in table 3.5. Although the formation of ATXN3 aggregates 
requires treatment of the neurons with glutamate, untreated neurons were used for 
experiments to decipher dysregulations in mRNAs and miRNAs which might be involved 
in the pathogenic mechanisms apart from the obvious, i.e. the toxicity mediated by the 
formation of ATXN3 aggregates. The 8 week old neurons were used for extraction of total 
RNA including small RNAs as well as the extraction of total protein. The total RNA was 
used to generate gene expression and miRNA expression profiles using the technique of 
RNA sequencing (RNA-seq). Proteins extracted from these neurons were utilized for 
quantification of proteins by immunoblotting. The expression of wild type and mutant 
alleles of ATXN3 in the SCA3 neurons was validated by immunoblotting using total 
proteins extracts as shown in figure 3.13. 
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 Age (yrs) at 
time of biopsy 
Sex Repeat length Age of onset 
Patient 1 40 male 74/21 30 
Patient 2 38 male 74/22 31 
Patient 3 42 female 73/27 28 
 Age (yrs) at 
time of biopsy 
Sex comments 
Control 1 24 female  
Control 2 68 male non-affected father of patient 1 
Table 3.5: Background details for the individual sources for the iPSC-derived 
neurons. The age of the individuals at the time of biopsy, sex, as well as the CAG repeat 
length and age of onset of the SCA3 symptoms for the SCA3 patients are included. 
 
Figure 3.13: ATXN3 expressed in iPSC-derived neurons from controls and SCA3 
patients. While the wild type ATXN3 allele (approx.50 kDa, thin arrow) is expressed in 
the controls and the SCA3 neurons, the expanded, mutant allele (approx.70 kDa, thick 
arrow) is expressed only in the SCA3 neurons.  
 
3.3.2 Gene expression profiling of SCA3 neurons 
Gene expression profiles were analysed by RNA-seq using the RNA extracted from the 
iPSC-derived neurons. The RNA-seq experiment was conducted by the group of Dr. 
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Stefan Bonn (Computational analysis of biological networks, DZNE Göttingen). Gene 
expression profiles of two controls were compared to the three SCA3 patients with the aim 
of finding dysregulated mRNAs in the SCA3 patient neurons. The gene expression 
profiles revealed that in SCA3 patient neurons, 71 mRNAs were dysregulated: 41 were 
upregulated and 30 were downregulated compared to healthy controls. The top five 
upregulated and downregulated genes in the SCA3 neurons are shown in table 3.6. (The 
complete list of dysregulated mRNAs is given in the appendix).  
Gene symbol 
 
 
Gene name 
Fold change in 
SCA3 neurons 
FDR          
P-value 
Genes upregulated in SCA3 neurons 
ELAVL2 
ELAV like neuron specific 
RNA-binding protein 2 4.94 8.37E-03 
KIAA1549L KIAA1549-like 4.3 4.00E-02 
ANK3 
ankyrin 3, node of Ranvier 
(ankyrin g) 3.96 2.26E-03 
DCC DCC netrin 1 receptor 3.81 2.00E-02 
MEX3A 
mex3 RNA-binding family 
member A 3.37 1.96E-04 
Genes downregulated in SCA3 neurons 
COLEC12 
collectin sub-family member 
12 -24.41 4.80E-15 
SERPINF1 
serpin peptidase inhibitor, 
clade F -14.26 4.10E-07 
LUM lumican -10.29 6.29E-38 
EFEMP2 
EGF containing fibulin like 
extracellular matrix protein 2 -6.81 7.01E-04 
EVA1C eva-1 homolog C (C.elegans) -5.82 5.00E-02 
Table 3.6: The five most upregulated and downregulated genes in SCA3 neurons. 
Genes have been displayed with fold change in expression in the SCA3 neurons as 
compared to healthy controls along with the P-values of differential expression. 
 
Results  
66 
 
To understand the relevance of the dysregulation of specific gene expression, the set of 
dysregulated mRNAs was analysed using techniques of Gene Ontology (GO) term 
enrichment, Pathway enrichment analysis and Protein interaction analysis.  
 
3.3.3 Gene Ontology (GO) term enrichment analysis 
The GO term enrichment analysis elucidated the enrichment of the dysregulated genes 
with respect to three categories, namely: molecular function, biological process and 
cellular component. As seen in table 3.7, the top ranked enriched GO terms pertaining to 
molecular function were associated with structural molecule activity, cytoskeletal 
regulation and poly(A) RNA binding. The dysregulation status (up or downregulation) of 
mRNAs in each of these terms is shown in figure 3.14. The top ranked enriched GO terms 
with respect to biological process revealed that the dysregulated genes were associated 
with neuron projection, neuron development, axon development, neuron differentiation 
and neurogenesis (table 3.8). The up and downregulated genes related to each of these 
terms is shown in figure 3.15. The top ranked GO terms associated with cellular 
component revealed an enrichment of genes associated with cell projection, neuron 
projection and axon (table 3.9). The split-up of the dysregulated genes related to each 
term is shown in figure 3.16. It is worth noting that the enrichment of the genes as 
ascertained by the False Discovery Rate (FDR) corrected p-values, is highest for the terms 
in the category biological process, followed by cellular component and molecular function 
in that order. 
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Gene 
ontology ID Name 
FDR P-
value 
Genes dys-
regulated 
in SCA3 
neurons 
Total 
genes in 
the GO 
term 
GO:0005198 structural molecule activity 9.24E-03 11 641 
GO:0005519 
cytoskeletal regulatory protein 
binding 1.36E-02 2 4 
GO:0008092 cytoskeletal protein binding 2.04E-02 11 792 
GO:0044822 poly(A) RNA binding 3.14E-02 13 1160 
GO:0043495 protein anchor 3.23E-02 2 9 
Table 3.7: The top ranked GO terms relating to molecular function enriched for the 
dysregulated mRNAs in the iPSC-derived SCA3 neurons.  
 
 
 
Figure 3.14: The downregulated and upregulated mRNAs included in each enriched 
GO term relating to the category ‘molecular function’.  
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Gene 
ontology ID Name 
FDR P-
value 
Genes dys-
regulated 
in SCA3 
neurons 
Total 
genes in 
the GO 
term 
GO:0031175 neuron projection development 6.41E-08 20 878 
GO:0048666 neuron development 6.41E-08 21 1009 
GO:0061564 axon development 2.76E-07 16 590 
GO:0030182 neuron differentiation 2.76E-07 22 1257 
GO:0022008 neurogenesis 4.81E-07 23 1441 
Table 3.8: The top ranked GO terms relating to biological process enriched for the 
dysregulated mRNAs in SCA3 neurons. 
 
 
 
 
Figure 3.15: The upregulated and downregulated mRNAs included in the enriched 
GO terms corresponding to the category ‘biological process’. 
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Gene 
ontology ID Name 
FDR P-
value 
Genes dys-
regulated 
in SCA3 
neurons 
Total 
genes in 
the GO 
term 
GO:0042995 cell projection 1.19E-06 24 1711 
GO:0043005 neuron projection 5.52E-06 17 945 
GO:0097458 neuron part 8.61E-06 18 1130 
GO:0030424 axon 1.24E-03 9 409 
GO:0044463 cell projection part 2.34E-03 12 839 
Table 3.9: The top ranked GO terms enriched for the dysregulated mRNAs in SCA3 
neurons corresponding to the category ‘cellular component’. 
 
 
 
Figure 3.16: The upregulated and downregulated mRNAs in SCA3 neurons 
corresponding to the top ranked GO terms in the category ‘cellular component’. 
 
 
Results  
70 
 
3.3.4 Pathway enrichment analysis 
The genes whose expression was dysregulated in SCA3 patient neurons were also 
analysed for enrichment or over-representation of genes associated with particular 
pathways. This analysis was conducted using the Reactome pathway database. Table 3.10 
displays the results of the top ranked pathways with the respective P-values for 
enrichment. The axon guidance pathway was the top ranked pathway with 8 of the 
dysregulated genes coding for proteins that are members of this pathway. The 
‘developmental biology’ pathway that includes 9 of the dysregulated genes is a group of 
pathways, which includes the axon guidance pathway. The other three pathways in the list, 
namely: Role of second messengers in netrin-1 signaling, Semaphorin interactions, 
interaction between L1, and Ankyrins are all ‘daughter pathways’, which are among the 
subsets of the axon guidance pathway. The list of dysregulated genes associated with each 
pathway is given in the appendix. 
Reactome 
Pathway ID Name 
FDR P-
value 
Genes dys-
regulated 
in SCA3 
neurons 
Total  
genes in 
the 
pathway 
REACT-
18266 Axon guidance 1.76E-02 8 345 
REACT-
111045 Developmental Biology 4.20E-02 9 531 
REACT-
22228 
Role of second messengers in 
netrin-1 signaling 1.22E-01 2 10 
REACT-
19271 Semaphorin interactions 2.71E-01 3 67 
REACT-
22266 
Interaction between L1 and 
Ankyrins 2.71E-01 2 31 
Table 3.10: Pathways enriched for the genes dysregulated in SCA3 neurons. The axon 
guidance pathway is the most enriched with 8 of the 71 dysregulated genes expressing 
proteins associated with this pathway.  
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3.3.5 Protein interaction analysis 
The genes dysregulated in SCA3 patient neurons were also analysed using the protein 
interaction database STRING-DB. The input list fed into the algorithm included the 71 
dysregulated mRNAs and the addition of ATXN3, with the aim of elucidating if proteins 
expressed from the dysregulated genes interact with ATXN3. The results are displayed in 
Figure 3.17 as a graphic, where each dysregulated gene product i.e. the resultant protein is 
denoted by a sphere. Proteins with known interactions (interactions validated from 
published experiments) are connected by lines. The ATXN3 protein is highlighted in the 
figure. The only protein known to interact with ATXN3 from amongst all the candidates is 
the DNAJB1 protein, coded by the DNAJB1 gene which is found to be downregulated in 
SCA3 patient neurons. The DNAJB1 protein is a well-studied chaperone (also known as 
one of the Hsp40 chaperones) and has been documented to co-localize with intra-nuclear 
inclusions, which are mediated by the expanded ATXN3 in SCA3 neurons (Seidel et al, 
2012a). 
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Figure 3.17: Protein interaction analysis reveals the DNAJB1 protein as an 
interaction partner of ATXN3. Using the STRING database, network analysis was done 
for all the proteins expressed by the genes dysregulated in SCA3 neurons. The ATXN3 
protein was added to the analysis to check which of the proteins are validated interaction 
partners. The DNAJB1 protein is the only protein that has been validated to interact with 
it. 
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3.3.6 MicroRNA expression profiling of the SCA3 neurons 
From the miRNA expression profile, it was found that in the SCA3 patient neurons, a total 
of 90 miRNAs were dysregulated. 71 miRNAs were upregulated and 19 miRNAs were 
downregulated compared to healthy controls. The top five miRNAs up and downregulated 
(in terms of fold-change) are as shown in table 3.11. 
 
miRNA name 
Fold change in iPSC- 
derived SCA3 neurons 
 
FDR P-value 
miRNAs upregulated in SCA3 neurons 
hsa-miR-431-5p 586.6214 1.27E-07 
hsa-miR-337-5p 352.2233 3.55E-06 
hsa-miR-770-5p 191.9895 7.60E-07 
hsa-miR-376a-3p 182.4585 1.78E-06 
hsa-miR-539-5p 134.6055 7.88E-05 
miRNAs downregulated in SCA3 neurons 
hsa-miR-449a -108.2534889 1.78E-03 
hsa-miR-449c-5p -93.32553078 9.54E-03 
hsa-miR-449b-5p -80.34681096 1.78E-03 
hsa-miR-199a-5p -66.25275354 3.01E-02 
hsa-miR-4490 -65.61140287 3.85E-03 
Table 3.11: The five most upregulated and downregulated miRNAs in SCA3 neurons.  
miRNAs have been displayed along with fold change in expression in the iPSC-derived 
SCA3 neurons as compared to healthy controls along with the P-values of differential 
expression.  
 
The miRNAs that were dysregulated in patients were analysed to check if their predicted 
targets were enriched in a particular pathway(s). This analysis was conducted using the 
web-based tool miRSystem, which considers predicted as well as validated miRNA targets 
(Lu et al, 2012).  The miRSystem tool uses the Reactome pathway database to identify the 
association of a specific gene with a pathway. As seen in Table 3.12, pathways were 
ranked according to their score, where the score was calculated using an algorithm that 
considers the absolute value of fold change of the miRNAs and the enrichment of its target 
genes in a particular pathway. The Axon guidance pathway had the highest score with 61 
of the dysregulated miRNAs predicted to target 165 out of a total 266 genes in this 
pathway. The second ranked pathway was the developmental biology, where 237 out of 
494 genes were predicted to be targeted by 61 of the dysregulated miRNAs. As mentioned 
in the gene expression pathway analysis, the developmental biology pathway in fact 
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constitutes a group of pathways, of which axon guidance pathway is a part. Other 
pathways that were amongst the top ranked were the L1CAM interactions pathway (a sub-
pathway of the axon guidance pathway), the neuronal system pathway, and the 
homeostasis pathway (both independent from the first three pathways).   
Reactome 
pathway 
ID 
Reactome pathway 
name 
Total 
genes of 
the term 
Genes as 
predicted 
targets of 
dys-regulated 
miRNAs 
Dys-
regulated 
miRNAs 
with 
predicted 
targets Score 
REACT-
18266 Axon guidance 345 165 61 1.955 
REACT-
111045 
Developmental 
biology 531 237 61 1.931 
REACT-
22205 L1CAM interactions 111 63 57 1.25 
REACT-
13685 Neuronal system 280 131 60 1.14 
REACT-
604 Hemostasis 512 215 62 1.124 
Table 3.12: Prediction for specific pathways enriched with putative targets of 
miRNAs dysregulated in SCA3 neurons. Table shows total genes associated with each 
pathway, along with the number of genes which are putative targets and the number of 
dysregulated miRNAs predicted to target the mRNAs of these genes.  
 
A combined analysis for the axon guidance pathway was done considering the pathway 
analysis of the mRNAs dysregulated in the gene expression profile (table 3.10) and the 
pathway analysis of the dysregulated miRNAs in the miRNA profile (table 3.12). 
According to the Reactome pathway database, 345 proteins are involved in the axon 
guidance pathway. In the iPSC-derived SCA3 neurons, the mRNAs for 8 of these were 
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dysregulated. On the other hand, 61 miRNAs predicted to target 165 mRNAs of the axon 
guidance pathway were also dysregulated in SCA3 neurons. 7 out of the 8 dysregulated 
mRNAs were among the predicted targets as shown in figure 3.18. (Names of the  
dysregulated genes have been provided in the appendix). As seen in the figure, the 
mRNAs of each of these proteins was targeted by multiple miRNAs with a mixed pattern 
of up and downregulation.    
 
 
Figure 3.18: Analysis of the mRNAs and miRNAs involved in the axon guidance 
pathway that are dysregulated in iPSC-derived SCA3 neurons. Of a total of 345 
proteins in the axon guidance pathway, the mRNAs of 165 are predicted to be targeted by 
the dysregulated miRNAs. The mRNAs of 7 of these exhibit significant dysregulation. 
These seven proteins are coloured either in green (mRNA upregulated) or red (mRNA 
downregulated). The targeting miRNAs are also displayed as green (upregulated) or red 
(downregulated) in SCA3 neurons as compared to control neurons. 
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3.3.7 Target selection from gene expression and miRNA expression profiling for 
further validation  
The next step after the high throughput RNA-seq experiment was to choose targets, which 
might be relevant to SCA3 pathogenesis and whose dysregulation in the iPSC-derived 
SCA3 neurons might be due to miRNA targeting.  
In the SCA3 neurons, the dysregulated mRNAs that are involved in the axon guidance 
pathway and are predicted targets of dysregulated miRNAs are obvious choices (table 
3.10). However, none of the proteins coded by these mRNAs are known and 
experimentally validated interaction partners of ATXN3. Also, choosing the right 
candidate(s) for validation, when several proteins involved in the axon guidance pathway 
might be modulated by the dysregulated miRNAs, is complicated. Hence, priority for 
validation was given to another gene, whose mRNA is dysregulated in the SCA3 neurons, 
namely: the DNAJB1 gene that codes for the DNAJB1 chaperone protein. 
The DNAJB1 chaperone is known to interact with intranuclear inclusions formed in SCA3 
as well as other polyQ diseases (Seidel et al, 2012a). In the gene expression profile from 
the iPSC-derived neurons, the DNAJB1 mRNA was one of the 71 dysregulated mRNAs 
with a 2.56 fold downregulation (or -2.56) in the profiles from 3 SCA3 neuronal cell lines 
compared to 2 control cell lines. As is evident from the protein interaction analysis of the 
gene expression profile (figure 3.17), DNAJB1 is the only protein of the 71 proteins 
coded by the dysregulated mRNAs that is known to directly interact with ATXN3. Also, 
11 of the 90 dysregulated miRNAs in SCA3 neurons are predicted to target the DNAJB1 
mRNA via binding at specific target sites on the 3’UTR of DNAJB1 mRNA according to 
the target prediction tool TargetScan (table 3.13).  
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miRNA name Fold change in iPSC- 
derived SCA3 neurons 
Conservation of DNAJB1 
3’UTR binding site across 
species 
DNAJB1 targeting miRNAs upregulated in SCA3 neurons 
hsa-miR-370 45.14309 Conserved 
hsa-miR-543 25.32928 Conserved 
hsa-miR-299-3p 33.5104 Poorly conserved 
hsa-miR-377-3p 35.65163 Poorly conserved 
hsa-miR-379-5p 48.05916 Poorly conserved 
hsa-miR-485-5p 38.617 Poorly conserved 
hsa-miR-494 45.15569 Poorly conserved 
DNAJB1 targeting miRNAs down  
regulated in SCA3 neurons 
hsa-miR-449a -108.2534889 Conserved 
hsa-miR-449b-5p -80.34681096 Conserved 
hsa-miR-143-3p -17.50185064 Poorly conserved 
hsa-miR-193a-3p -13.50312411 Poorly conserved 
Table 3.13: miRNAs dysregulated in SCA3 neurons with predicted binding sites on 
the 3’UTR of DNAJB1 mRNA. Profiling data from 3 SCA3 neuronal cell lines and 2 
control neuronal cell lines. The target predictions were done using the TargetScan tool. 
Seven of the dysregulated miRNAs are upregulated while four are downregulated in SCA3 
neurons. The conservation of the each miRNA binding site across species is also denoted.  
 
Once DNAJB1 was chosen as a candidate to be validated as a miRNA target of relevance 
in SCA3, the succeeding experiments dealt with the following points: 
 Quantification of DNAJB1 mRNA and protein levels in iPSC-derived neurons. 
 Validation of the ability of specific miRNAs to bind at specific binding sites on 
the 3’UTR of DNAJB1 mRNA. 
 Analysis of the miRNAs’ effect on endogenous DNAJB1 mRNA and protein 
levels in human cell lines. 
 Analysis of the miRNAs’ effect on aggregation of expanded ATXN3. 
 Quantification of DNAJB1 mRNA and protein levels in a transgenic mouse model 
of SCA3. 
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3.3.8 Quantification of DNAJB1 mRNA and protein levels in iPSC-derived neurons 
The quantification of DNAJB1 mRNA and protein levels in the iPSC-derived neurons was 
the first step in the validation of DNAJB1 as a miRNA target in SCA3. DNAJB1 mRNA 
levels were analysed by real-time PCR with the aim of verifying the results of the gene 
expression profile in which the SCA3 neurons had a -2.56 fold downregulation in the 
DNAJB1 mRNA compared to controls. As shown in figure 3.19, the DNAJB1 mRNA 
levels are significantly lower in the SCA3 patients as compared to the controls.  
 
Figure 3.19: DNAJB1 mRNA levels are reduced in the SCA3 neurons as compared to 
the controls.  DNAJB1 and beta-actin mRNA levels (as loading control) were checked by 
SYBR Green real-time PCR. Columns represent values +/- standard deviation from 2 
control neuronal cell lines (controls) and 3 SCA3 neuronal cell lines (patients). 
 
The DNAJB1 protein level in the iPSC-derived neurons was quantified by immunoblotting 
using an antibody against DNAJB1 as shown in figure 3.20a. On quantification and 
normalization of the signal intensities to the housekeeping protein alpha tubulin, it is 
evident that the SCA3 neurons have a reduced level of DNAJB1 protein as compared to 
the control neurons (figure 3.20b).   
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Figure 3.20: DNAJB1 protein levels are reduced in SCA3 neurons as compared to the 
controls. DNAJB1 (A; upper panel) and alpha-tubulin (A; lower panel) protein levels 
were determined by immunoblotting against specific antibodies. As shown in (B) the 
DNAJB1 protein levels were quantified based on the ratio of DNAJB1 to the loading 
control alpha-tubulin. Columns represent values +/- standard deviation from 2 control 
neuronal cell lines (controls) and 3 SCA3 neuronal cell lines (patients). 
 
3.3.9 Validation of the ability of specific miRNAs to bind at specific binding sites on 
the 3’UTR of DNAJB1 mRNA 
From the dysregulated miRNAs predicted to target the 3’UTR of DNAJB1 mRNA, four 
miRNAs were chosen for validation experiments: miR-543, miR-370, miR-449a and miR-
143. These miRNAs were chosen because they are highly dysregulated in the SCA3 
neurons (table 3.13) and because the binding sites of three of them (miR-543, miR-370 
and miR-449a) are conserved across species. miR-370 has two conserved binding sites on 
DNAJB1 3’UTR. The 3’UTR of DNAJB1 mRNA is 1170 nt long. The locations of the 
binding sites for the chosen miRNAs are shown in figure 3.21. 
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Figure 3.21: A pictorial representation of the DNAJB1 3’UTR with the locations of 
the binding sites of the selected miRNAs.   
 
To validate the ability of these miRNAs to target specific sites on the DNAJB1 3’UTR, 
the 3’UTR was cloned into the luciferase reporter vector psiCHECK-2. As in previous 
sections, the 3’UTR was fused to Renilla luciferase. The binding sites for the four chosen 
miRNAs were mutated by substitutions of two nucleotides complementary to positions 2, 
3 on the miRNA seed region. An example of this is shown in figure 3.22, where the miR-
543 binding site mutant is depicted (figures for the other miRNA binding site mutants are 
included in the appendix).  
 
Figure 3.22: Representation of miR-543 binding to DNAJB1 3’UTR at its predicted 
binding site. The binding of miR-543 to the wild type DNAJB1 3’UTR is shown in (A), 
and the disruption of binding caused by mutations at two nucleotides in the miR-543 
binding site in DNAJB1 3’UTR is shown in (B).     
 
To analyse if the specific miRNAs target at their predicted binding sites, Hela cells were 
transfected with constructs containing either the wild type 3’UTR of DNAJB1 or the 
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3’UTR with miRNA binding site mutants. Cells were lysed 48 hours after transfections 
and the Renilla and Firefly signals from the cell lysates were measured in the luciferase 
assay. Mutations at the binding sites for miR-143, miR-449a and miR-543 in the DNAJB1 
3’ UTR led to an increased signal ratio of Renilla/Firefly luciferase (figure 3.23) 
suggesting that the mutations led to a decrease in miRNA targeting of the Renilla-
DNAJB1 3’UTR mRNA. Therefore the endogenously expressed miRNAs from the Hela 
cells were able to target their predicted binding sites on DNAJB1 3’UTR. Mutating either 
one or both the binding sites of miR-370 on DNAJB1 3’UTR also led to an increased 
signal ratio of Renilla/Firefly luciferase (figure 3.24). The double mutant with both 
binding sites mutated gave a significantly increased signal ratio compared to the mutants 
with either the first or the second miR-370 binding site mutated. This suggests that 
although miR-370 can target the DNAJB1 3’UTR by binding at either of its two binding 
sites, the targeting is enhanced by binding at both the sites. 
 
Figure 3.23: Mutations of miRNA binding sites in DNAJB1 3’UTR lead to increased 
Renilla/Firefly signal ratio. Binding sites of miR-143, miR-449 or miR-543 in DNAJB1 
3’UTR sequence in psiCHECK-2 vector were mutated. Wild type and mutant constructs 
were transfected in Hela cells and Renilla, Firefly luciferase signals measured 48 hours 
after transfection. Columns represent values +/- standard deviation. n = 27, P-value = 
0.0001 
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Figure 3.24: Mutations of miR-370 binding sites in DNAJB1 3’UTR lead to increased 
Renilla/Firefly signal ratio. Both the binding sites of miR-370 in DNAJB1 3’UTR 
sequence in psiCHECK-2 vector were mutated. Wild type and mutant constructs were 
transfected in Hela cells and Renilla, Firefly luciferase signals measured 48 hours after 
transfection. Columns represent values +/- standard deviation. n = 27, P-value = 0.0002  
 
3.3.10 Analysis of the miRNAs’ effect on endogenous DNAJB1 mRNA and protein 
levels in human cell lines  
DNAJB1 mRNA and protein were downregulated in iPSC-derived SCA3 neurons (figure 
3.19 and figure 3.20 resp.), whereas the miRNA expression profile suggested that miR-
370 and miR-543 were upregulated in iPSC-derived SCA3 neurons as compared to control 
neurons (table 3.13). Hence the relationship between DNAJB1 mRNA, protein and these 
miRNAs fits exactly to what would be expected from a miRNA-target pair. The results 
from the luciferase assays support this assumption. Therefore, miRNAs miR-370 and miR-
543 were analysed for their ability to modulate DNAJB1 mRNA and protein expression. 
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To analyse their ability to modulate DNAJB1 mRNA and protein expression, miR-370 and 
miR-543 were overexpressed in Hela cells using their mimic oligonucleotides. Hela cells 
were transfected with miR-370 and miR-543 mimics for 48 hours. Cell lysates were 
immunoblotted to analyse the DNAJB1 protein levels whereas RNA extracted from the 
transfected cells and further reverse transcribed into cDNA was used for analysing the 
DNAJB1 mRNA in the cells by SYBR green real time PCR.  
The overexpression of miR-370 and miR-543 led to a significant decrease in DNAJB1 
mRNA levels 48 hours after transfections (figure 3.25). Consequently an accompanying 
substantial decrease in DNAJB1 protein expression was also seen in immunoblots (figure 
3.26). 
 
Figure 3.25: Overexpression of miR-370 and miR-543 decreases DNAJB1 mRNA 
levels in Hela cells. miR-370 and miR-543 mimics were co-transfected in Hela cells.  
DNAJB1 and GAPDH mRNA levels (as loading control) were checked by SYBR Green 
real-time PCR 48 hours after the transfection. Columns represent values +/- standard 
deviation. n = 3, P-value = 0.0047  
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Figure 3.26: Overexpression of miR-370 and miR-543 decreases DNAJB1 protein 
levels in Hela cells. miR-370 and miR-543 mimics were co-transfected in Hela cells. The 
DNAJB1 (A; upper panel) and alpha-tubulin (A; lower panel) protein levels 48 hours post 
transfection were determined by immunoblotting using specific antibodies. As shown in 
(B) the DNAJB1 protein levels were quantified based on the ratio of DNAJB1 to the 
loading control alpha-tubulin. Columns represent percentage value of MID1/alpha-tubulin 
ratio. 
 
3.3.11 Analysis of the miRNAs’ effect on aggregation of expanded ATXN3 
Since DNAJB1 has been shown to colocalize with aggregates formed by expanded 
ATXN3, an experiment was set up to check the effect of miR-370 and miR-543 
overexpression on DNAJB1 expression and ATXN3 aggregate formation in Hela cells. 
Hela cells were co-transfected with miR-370, miR-543 mimics and myc-tagged c-terminal 
Q71 ATXN3 cloned into the pcDNA 3.1 construct (kind gift from Dr. P Breuer, Uniklinik 
Bonn) for 48 hours. Cells were immunostained with antibodies against myc or DNAJB1, 
followed by secondary antibodies tagged with Cy3 and Alexa 647 respectively.  As shown 
in figure 3.27, c-terminal Q71 ATXN3 formed aggregates in a certain percentage of cells 
(green signal). No visible co-localization of DNAJB1 (red signal) with the aggregates was 
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seen in cells co-transfected with either control siRNA (figure 3.27A) or miR-370 and 
miR-543 mimics (figure 3.27B). Upon counting cells with aggregates, around 12.6% cells 
co-transfected with control siRNA and c-terminal Q71 ATXN3 had aggregates, while 
around 7.4% of the cells co-transfected with miR-370, miR-543 and c-terminal Q71 
ATXN3 had aggregates, thus exhibiting no significant difference in the number of cells 
bearing aggregates upon co-transfection with either the control siRNA or miR-370, miR-
543 mimics.  
 
Figure 3.27: Transfection of miR-370, miR-543 does not alter aggregation of 
expanded ATXN3. Upon co-transfection of Hela cells with the aggregate prone c-
terminal Q71 ATXN3 with either control siRNA (A) or miR-370, miR-543 (B) no 
significant differences in the number of cells bearing aggregates were seen.   
 
3.3.12 Quantification of DNAJB1 mRNA and protein levels in a transgenic mouse 
model of SCA3 
B6.SCA3-YAC-84Q mice expressing the human ATXN3 gene with 84 CAG repeats have 
been shown to exhibit SCA3 related symptoms such as motor dysfunction, progressive 
ataxia, presence of ATXN3 aggregates in neurons (Cemal et al, 2002). DNAJB1 mRNA 
and protein levels were checked in hindbrains of 6 month old male control and SCA3 
mice. As shown in figure 3.28, DNAJB1 mRNA levels in the SCA3 mice were reduced as 
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compared to the controls. However no significant difference was seen in DNAJB1 protein 
levels in the SCA3 mice as compared to the controls as seen in figure 3.29.  
 
Figure 3.28: DNAJB1 mRNA levels are reduced in the hindbrains of transgenic 
SCA3 mice as compared to wild type mice. DNAJB1 and GAPDH mRNA levels (as 
loading control) were checked by SYBR Green real-time PCR. Columns represent values 
+/- standard deviation. n = 4, P-value = 0.0004  
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Figure 3.29: DNAJB1 protein levels are unchanged in the hindbrains of transgenic 
SCA3 mice as compared to wild type mice. DNAJB1 (A; upper panel) and beta.actin (A; 
lower panel) protein levels were determined by immunoblotting using specific antibodies. 
As shown in (B) the DNAJB1 protein levels were quantified based on the ratio of 
DNAJB1 to the loading control beta-actin. Columns represent values +/- standard 
deviation. n = 4, P-value = 0.5431  
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Chapter 4 Discussion 
 
MicroRNAs are important regulators of gene expression and have been linked to several 
diseases including neurodegenerative diseases. In this study, miRNAs that modulate the 
expression of specific proteins relevant in the pathogenesis of SCA3 were investigated. 
Two miRNAs, hsa-miR-32 and hsa-miR-181c were found to target ATXN3, the protein 
mutated in SCA3. Moreover, the study revealed the ability of three miRNAs, hsa-miR-
216a-5p, hsa-miR-374a and hsa-miR-542-3p to target MID1, a protein that stimulates the 
translation of expanded CAG repeat mRNAs. Finally, two miRNAs, namely hsa-miR-370 
and hsa-miR-543 were ascertained to target DNAJB1, a chaperone that has been shown to 
play a role in prevention of SCA3 toxicity. This study suggests that these miRNAs might 
act as disease modifiers in SCA3 due to their ability to target the expression of proteins 
playing a role in the cell toxicity observed in SCA3. 
 
4.1 miRNAs target ATXN3 3’UTR and downregulate ATXN3 mRNA and protein 
expression  
Polyglutamine diseases are characterized by the expression of mutant proteins with 
expanded glutamine repeats. The mutant proteins form aggregates into which several other 
proteins are sequestered contributing to the neurotoxicity observed in polyQ diseases 
(McCampbell et al, 2000; Perez et al, 1998). Several cellular mechanisms such as 
regulation of protein folding or proteasomal degradation of the aggregate prone proteins 
suppress aggregate formation and toxicity (Chai et al, 1999b). The neuronal cell death 
seen in the brains of polyQ disease patients over several years can be considered as a 
result of a lost battle by the neurons trying to restrict the expression of the mutant protein 
as well as other neurotoxic proteins, while at the same time maintaining the expression of 
neuroprotective proteins. miRNAs are important for the regulation of gene expression with 
up to 30% of human genes estimated to be regulated by miRNAs (Lewis et al, 2005). 
Studies are gradually casting a light on the crucial role miRNAs play in the pathogenic 
mechanisms in polyQ diseases. Previous studies have shown that the mutant proteins 
whose expression is the basis of toxicity in polyQ diseases are directly targeted by 
miRNAs and disease progression is modulated by the expression of miRNAs. This has 
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been shown to be the case for DRPLA (Karres et al, 2007) and SCA1 (Lee et al, 2008; 
Persengiev et al, 2011). In this study, miRNAs predicted to target the 3’UTR of ATXN3 
were analysed and the ability of five candidate miRNAs: miR-9, miR-32, miR-125a-5p, 
miR-181c and miR-383 to target ATXN3 3’UTR at specific binding sites was validated. 
These studies suggest that all the five miRNAs are able to target the ATXN3 3’UTR at 
their specific binding sites. The targeting by two of the five miRNAs could be verified, 
namely miR-32 and miR-181c led to a downregulation of expression of ATXN3 mRNA 
and protein. miR-32 and miR-181c have been previously shown to be associated with the 
spread of tumours in colorectal carcinoma and breast cancer respectively (Tominaga et al, 
2015; Wu et al, 2013), however this is the first study implicating these miRNAs in the 
regulation of ATXN3 expression. Individual overexpression of either miR-32 or miR-181c 
did not yield a substantial decrease in ATXN3 levels (data not shown), while a 
combination of both miRNAs did. This is not surprising, since there is evidence that 
miRNAs function in combination to effectively repress the expression of a common target 
mRNA (Vo et al, 2010; Wu et al, 2010). The 3’UTR sequence of wild type and mutant 
ATXN3 is identical, therefore miR-32 and miR-181c can be expected to downregulate 
both the wild type and the mutant allele of ATXN3. Huang et al have recently shown the 
ability of miR-25 to downregulate wild type as well as mutant ATXN3, leading to a 
decrease in cell toxicity in a SCA3 model (Huang et al, 2014). miR-25 binds to ATXN3 
3’UTR at the same binding site as miR-32 with similar predicted efficiency. These results 
taken together suggest that several miRNAs target the ATXN3 3’UTR and regulate 
ATXN3 protein expression. Unravelling multiple miRNAs, which target ATXN3, will 
help to identify a pool of miRNAs which can be used to build a therapeutic strategy. Using 
such a pool will help to overcome the problems of high concentrations of individual 
miRNAs and the resultant off target effects. 
Further experiments regarding miRNA targeting of ATXN3 would include the use of 
lentiviral mediated delivery of miRNAs to iPSC-derived SCA3 neurons. This would verify 
the ability of these miRNAs to modulate the expression of the mutant ATXN3 allele as 
well as the formation of microaggregates that are formed in these neurons upon glutamate 
excitation (Koch et al, 2011). Alternately, such a lentiviral delivery approach could be 
used to assess miRNA mediated control of expanded ATXN3 expression in YAC 
transgenic mice carrying the expanded ATXN3 locus, or primary neuronal cells prepared 
from these mice (Cemal et al, 2002). Although miRNA mediated targeting of ATXN3 is 
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not exclusive for the mutant allele (since the mutant and the wild type allele share the 
same 3’UTR sequence), a decrease in the wild type ATXN3 as a side-effect might not be 
deleterious to the cells. Studies in ATXN3 knock-out mice have shown that these mice, 
despite the absence of ATXN3 are viable and fertile (Schmitt et al, 2007; Switonski et al, 
2011). Hence, miRNA targeting of ATXN3 might be a viable strategy to counter SCA3 
toxicity. 
 
4.2 miRNAs target MID1 3’UTR and downregulate MID1 mRNA and protein 
expression 
Apart from targeting the mutant proteins in polyQ diseases, there is growing evidence that 
miRNAs also modulate the expression of other proteins that contribute to neurotoxicity in 
polyQ diseases. In several cases, the disease progression is associated with reduced 
expression of these miRNAs leading to an elevated expression of their neurotoxic targets. 
In HD, it has been shown that reduced levels of miRNAs as a result of transcriptional 
repression by the REST repressor results in elevated levels of miRNA targets, which 
might be associated with the  pathogenicity of HD (Johnson et al, 2008). A study in animal 
and cell models of SCA3 has shown that reduced expression of miRNAs as a result of 
mutation in miRNA processing proteins causes enhanced toxicity of the mutant ATXN3 
protein suggesting that miRNAs play a protective role by controlling the expression of 
pathogenic proteins (Bilen et al, 2006). The protein MID1 was chosen as a neurotoxic 
protein candidate for analysing miRNA targeting relevant to SCA3. MID1 is part of a 
protein complex that binds CAG repeat mRNAs in a length dependent manner and 
stimulates their translation to expanded polyQ repeat proteins. Although studies relevant 
to this observation were conducted in a HD model (Krauss et al, 2013), preliminary 
studies suggest that MID1 also binds to expanded ATXN3 mRNA in a length dependent 
manner (unpublished data according to personal communication with Dr. Sybille Krauss, 
DZNE Bonn). MID1 was therefore a valid candidate to study putative miRNA mediated 
regulation. This study revealed that three miRNAs: miR-216a-5p, miR-374a, miR-542-3p 
target the 3’UTR of MID1 at specific binding sites. Overexpression of these three 
miRNAs in HEK T-293 cells led to a decrease in endogenous levels of MID1 mRNA and 
protein in these cells. Previous studies have shown MID1 to be a target of miR-135b in 
breast cancer (Arigoni et al, 2013), however the ability of miR-216a-5p, miR-374a and 
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miR-542-3p to target MID1 has not been previously documented. Since MID1 binds and 
aids translation of ATXN3 mRNA in a length dependent manner, the miRNA mediated 
downregulation in MID1 might lead to reduction in the translation of the mutant ATXN3 
mRNA leaving the wild type allele unaffected. Furthermore, this miRNA mediated 
repression of MID1 expression might be beneficial for controlling polyQ toxicity beyond 
the repression of mutant ATXN3. It has been shown that the aggregates formed in polyQ 
neurons sequester other proteins containing glutamine stretches such as as TATA-binding 
protein (TBP), Eyes Absent (EYA) protein (Perez et al, 1998). Although it is not yet 
proven, MID1 might be able to bind and stimulate the expression of the CAG repeat 
mRNAs of these proteins as well. Therefore, a reduction in MID1 levels might function to 
reduce the expression of several proteins that partake in the formation of aggregates in 
polyQ diseases. Targeting of MID1 expression using miRNAs could also be a strategy 
employed in other CAG repeat disorders. 
Further experiments concerning the effects of miRNA targeting of MID1 expression on 
CAG repeat mRNAs are required to ascertain if miRNA targeting of MID1 might play a 
role in SCA3 and in general polyQ pathogenesis. Reporter constructs carrying different 
lengths of CAG repeats, which are available in the laboratory, will be used for further 
experiments (Krauss et al, 2013). 
 
4.3 The use of iPSC-derived SCA3 neurons to analyse SCA3 associated gene and 
miRNA expression  
In parallel to the studies to find miRNAs targeting the neurotoxic proteins ATXN3 and 
MID1, access was gained to a recent model system to study SCA3 pathogenesis, viz 
neurons derived from Induced Pluripotent Stem Cells (iPSCs) from SCA3 patients (Koch 
et al, 2011). The use of iPSCs as model systems to understand pathogenic mechanisms of 
diseases, as well as to device therapeutic strategies has been increasing in the recent years 
(Okano & Yamanaka, 2014; Park et al, 2008). As compared to other cell lines or animal 
models, an important advantage of the use of iPSCs is that they represent patient derived 
material that can be further differentiated into cells that are relevant to that particular 
disease. In the case of neurodegenerative diseases, the ability to differentiate iPSCs into 
neurons provides a very appropriate tool to study disease pathogenesis as well as device 
therapeutic strategies. iPSCs derived from primary cells such as fibroblasts or peripheral 
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blood lymphocytes from patients of several neurodegenerative diseases such as 
Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD) have 
been studied and in many cases these iPSCs have been further differentiated into neurons 
that exhibit pathogenic mechanisms associated with these disorders (Camnasio et al, 2012; 
Nguyen et al, 2011; Soldner et al, 2009; Yagi et al, 2011).  
Neurons used were differentiated from iPSCs derived from SCA3 patients and healthy 
controls to study changes in gene expression and miRNA expression profiles associated 
with the expression of the expanded CAG repeat containing ATXN3 allele. 
Microaggregates containing ATXN3 have been observed in these neurons upon excitation 
with glutamate or NMDA (Koch et al, 2011). However the neurons used in this study, 
were not subjected to glutamate excitation. The reason for this was the assumption that 
glutamate excitation and resulting flow of Ca
2+ 
ions into the neurons probably leads to 
massive and short term changes in gene expression and miRNA expression as the cells 
respond to the excitation. The focus in this study was understanding the differences in 
gene and miRNA expression in SCA3 and control neurons, which are associated with the 
expression of the mutant allele over a longer period of time, and hence, might be 
associated with the relatively slower acting mechanisms of cell toxicity.   
The RNA isolated from two control lines and three SCA3 lines of iPSC-derived neurons 
was used for mRNA and miRNA expression profiling. Although a higher number of 
samples would have been preferable in terms of the statistical strength of the results, 
additional cell lines were not available at that time.    
Comparison of the gene expression profiles of the SCA3 neurons with the control neurons 
revealed dysregulation in the expression of several genes. To understand the relevance of 
this dysregulation in terms of mechanisms that might be altered due to the presence of 
mutant ATXN3, the gene expression data was analysed using gene ontology analysis, 
pathway analysis and analysis of the interaction of proteins coded by the dysregulated 
genes with the ATXN3 protein.  
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Gene and miRNA expression profile suggests alterations in the axon guidance 
pathway and the DNAJB1 chaperone in the SCA3 neurons 
The gene and miRNA expression profiles from iPSC-derived control and SCA3 neurons 
were analysed using various tools which enabled analyses such as gene ontology analysis, 
pathway analysis and protein interaction analysis. The gene ontology analysis of the 
dysregulated genes is categorized into three categories: molecular function, biological 
process and cellular compartment. Considering the enriched terms in all three categories 
gives an idea of the significance of the dysregulated gene expression.  The enriched terms 
for molecular function of the dysregulated genes suggests that the SCA3 neurons might 
have altered structural molecule activity, cytoskeletal regulatory protein binding, 
cytoskeletal protein binding, poly(A) RNA binding and  protein anchor activity. The 
enriched terms for the biological processes associated with the dysregulated genes suggest 
that the SCA3 neurons have altered neuron development, especially axonal development. 
In terms of the cellular location of the proteins coded by the dysregulated genes, the 
enriched terms associated with cellular compartment suggest that the proteins are 
predominantly located in cellular projections, especially in axonal projections. In 
summary, the GO analysis of the dysregulated genes suggests that in comparison with the 
controls, the SCA3 neurons have alterations in the binding of cytoskeletal and RNA 
binding proteins which might be associated with changes in neurite outgrowth and axonal 
development, with localization of a significant number of dysregulated proteins in the 
cellular projections such as the axonal projections.    
The mechanisms suggested by the GO analysis are reinforced by the pathway analysis of 
the dysregulated genes as well as the dysregulated miRNAs in the SCA3 neurons. The 
pathway analysis of the dysregulated genes suggests that the SCA3 neurons might have 
alterations in the axon guidance pathway. Axon guidance is the process in which neuronal 
axons respond to guidance cues to grow and form synapses with specific target neurons 
eventually leading to the formation of a neuronal network (Tessier-Lavigne & Goodman, 
1996). The guidance cues for axons in this process are molecules expressed by other 
neurons and are either secreted or expressed on the cell surface. There are several classes 
of proteins such as netrins, semaphorins, Cell Adhesion Molecules (CAMs) that act as 
guidance cues enabling attraction or repulsion of axons (Varela-Echavarria & Guthrie, 
1997). The recognition of these guidance cues triggers downstream signalling cascades in 
the neurons that lead to appropriate response to the cues. The pathway analysis of the 
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dysregulated genes in the gene expression profile of SCA3 and control neurons suggests 
that the SCA3 neurons might have alterations in mechanisms included in axonal guidance 
pathway such as netrin-1 signalling, semaphorin signalling and interactions of the cell 
adhesion molecule L1. Several genes that are upregulated in SCA3 neurons code for 
proteins that aid in neurite outgrowth via interaction with netrins (such as the genes DCC, 
PITPNA), semaphorins (SEMA6A), neural cell adhesion molecules (ANK3, KCNQ2, 
ST8SIA2) or the cytoskeleton (MAP1B, MAP2). A higher level of neurite growth in the 
SCA3 neurons can be explained by observations from previous studies connecting the 
expression of polyQ proteins to altered axonal development and transport. Although 
polyQ inclusions, a hallmark of polyQ diseases, have been traditionally observed in 
neuronal soma, there are several studies showing the presence of such inclusions in axons. 
Axonal inclusions have been in seen in axonal fiber tracts that are degenerated in the 
brains of SCA3 patients and HD patient brains (Rub et al, 2014; Seidel et al, 2010). 
Besides, axonal inclusions have been observed in cell culture and animal models of HD 
(Krench & Littleton, 2013; Li et al, 2001), SBMA (Piccioni et al, 2002) and SCA3 (Cemal 
et al, 2002). These axonal inclusions interfere with axonal transport, leading to defects and 
even degeneration of neurites (Gunawardena & Goldstein, 2005; Li et al, 2001; Piccioni et 
al, 2002). There is also a suggestion that the mere presence of polyQ proteins disturbs 
retrograde and anterograde transport along the axons, even when the polyQ protein is not 
recruited into inclusions (Szebenyi et al, 2003). Therefore, the elevated neurite growth in 
SCA3 neurons as suggested by the profiling experiments might be a protective mechanism 
employed by the neurons in response to hindrances in axonal transport leading to 
disruption in the supply of molecules that are required in neurite growth. It is also possible 
that the elevated neurite growth is simply the result of the individual iPSC-derived cell 
lines being in varying stages of neuronal differentiation in culture. Conversely, the 
elevated neurite growth could also be associated with MID1 activity. The loss of MID1 
function is associated with enhanced axonal growth and elongation in mouse cortex due to 
the enhanced activity of PP2A which is targeted for degradation by MID1 (Lu et al, 2013). 
Although the study exhibiting this observation was not associated with a polyQ disorder, it 
is possible that in the SCA3 neurons the association of MID1 with expanded CAG repeat 
ATXN3 mRNA prevents it from carrying out its degradative function towards PP2A, 
leading to enhanced axonal growth.  Further studies are necessary to establish any 
relationship between MID1 and axonal growth in SCA3 neurons.  
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The pathway analysis of the putative targets of the miRNAs that are dysregulated in SCA3 
neurons also suggests an enrichment of the targeted genes involved in the axon guidance 
pathway. Many of the dysregulated miRNAs have putative targets in the axon guidance 
pathway and these miRNAs are upregulated as well as downregulated in the SCA3 
neurons. While most of the putative targets do not show altered mRNA levels in the SCA3 
neurons, a few targets are dysregulated as seen in the gene expression profile.  Although 
validation studies would be necessary prior to drawing conclusions, enrichment of the 
axon guidance pathway in both the gene as well as the miRNA expression profile suggests 
that miRNA targeting of gene expression plays a role amongst the mechanisms the SCA3 
neurons use to deal with the effects of the presence of pathogenic ATXN3. A short 
mention must be made here regarding the expression of miRNAs directly targeting the 
expression of ATXN3 and MID1 in the miRNA profile of the SCA3 neurons. As seen in 
the profiles, none of the miRNAs analysed to target ATXN3 or MID1 mRNA are 
dysregulated in the SCA3 neurons, neither are the ATXN3 or MID1 mRNAs. This 
suggests that in these particular neurons, miRNA mediated targeting of ATXN3 and MID1  
was either not active, or was carried out with other miRNAs which are not amongst those 
predicted to target ATXN3 or MID1 mRNAs.   
Protein interaction analysis was done to check if genes coding for known interaction 
partners of ATXN3 are dysregulated in SCA3 neurons. This analysis revealed that the 
chaperone DNAJB1, which is a known interaction partner of ATXN3, was downregulated 
in SCA3 neurons. DNAJB1 is one of the HSP40 chaperones and being a co-chaperone of 
HSP70, is essential for the ability of HSP70 to refold proteins that are misfolded (Michels 
et al, 1999). DNAJB1 plays a key role in the cellular response to polyQ aggregates 
including mutant ATXN3 aggregates in SCA3. It is known that DNAJB1 co-localizes with 
SCA3 aggregates and along with HSP70 is involved in the process of converting the toxic 
fibril like aggregates into amorphous aggregates which can be degraded (Muchowski et al, 
2000). Therefore, the maintenance of DNAJB1 expression levels in the cell would be 
important in counteracting the aggregate mediated toxicity seen in SCA3. However the 
gene expression profile suggested a downregulation in DNAJB1 mRNA in the SCA3 
neurons. Moreover, miRNA expression profile suggested that several miRNAs predicted 
to target the DNAJB1 mRNA by binding at 3’UTR are also dysregulated in SCA3 
neurons. Considering the importance of DNAJB1 in SCA3, miRNA targeting of DNAJB1 
occurring in SCA3 neurons as seen in the profiling experiments was validated. 
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4.4 miRNAs target DNAJB1 3’UTR and downregulate DNAJB1 mRNA and protein 
expression  
To validate the observed DNAJB1 modulation in the iPSC-derived SCA3 neurons as 
suggested by the profiling experiment, DNAJB1 mRNA and protein levels in SCA3 and 
control neurons were checked and it was found that there was indeed a downregulation in 
the levels of DNAJB1 mRNA as well as protein in SCA3 neurons. From amongst the 
dysregulated miRNAs predicted to target DNAJB1 3’UTR, four miRNAs: miR-143, miR-
370, miR-449c and miR-543 were able to target DNAJB1 3’UTR at specific binding sites. 
Furthermore the overexpression of two of these miRNAs, miR-370 and miR-543 led to a 
decrease in DNAJB1 mRNA and protein levels. So far, this is the first study exhibiting 
miRNA targeting of DNAJB1 in human cells. miR-370 and miR-543  have previously 
been associated with the spread of prostate cancer and hepatocellular carcinoma 
respectively but have not been previously shown to target any chaperone or be associated 
with any neurodegenerative disease (Wu et al, 2012; Yu et al, 2014).  
Since DNAJB1 is involved in modulation of toxic aggregate formation, miR-370 and miR-
543 were overexpressed to check if it led to any change in the formation of inclusions 
mediated by co-expression of the aggregate prone C-terminal fragment of expanded 
ATXN3. No significant changes in aggregate formation were detected. However, drawing 
conclusions from these experiments is difficult since the validation of whether the 
transfected individual cells receive both miRNAs and plasmids could not be performed.  
YAC transgenic mice carrying the expanded ATXN3 locus exhibit the formation of 
intranuclear inclusions along with progressive motor defects (Cemal et al, 2002). Levels of 
DNAJB1 in these YAC transgenic mice expressing the human ATXN3 transgene with 84 
CAG repeats were checked. Transgenic mice at the age of 52 weeks had SDS-insoluble 
ATXN3 aggregates in their brains (data not shown). The DNAJB1 mRNA levels in the 
hindbrains of these mice were reduced as compared to controls of the same age. However, 
there was no significant change in the DNAJB1 protein levels. However, since the RNA 
and protein quantification was conducted from mouse hindbrains, it is possible that any 
differences in the DNAJB1 protein amounts in the neurons are diluted by the presence of 
DNAJB1 from other cell types in the brain lysates. Owing to the lack of conservation in 
miRNA target sites between the 3’UTRs of DNAJB1 in humans and mice it could not 
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verified if miR-370 and miR-543 might be involved in targeting of DNAJB1 in the 
transgenic mice. However, the downregulation of DNAJB1 mRNA could be verified both 
in SCA3 neurons as well as the YAC transgenic mice and hence suggests that this might 
be a phenomenon associated with SCA3. 
This data suggests the existence of a new mechanism of pathogenesis in SCA3, wherein 
the dysregulation of miRNAs targeting DNAJB1 occurs, causing a decrease in the levels 
of DNAJB1 mRNA and protein. Owing to the neuroprotective nature of DNAJB1 via 
breakdown of aggregates, the decrease in its levels might be deleterious to the cells by 
enhancing aggregation of mutant ATXN3 and its associated toxicity. Although previous 
studies have shown a decrease in the cytosolic DNAJB1 protein levels in polyQ disease 
that is attributed to its sequestration into polyQ aggregates (Hay et al, 2004), a decrease on 
the transcript level has been shown for the first time in this study. An important question 
pertaining to the decreased DNAJB1 and increased miR-370, miR-543 levels is which is 
the cause and which is the effect? DNAJB1 is neuroprotective and studies have revealed 
that it’s overexpression might ameliorate the toxicity associated with expanded ATXN3 
(Chai et al, 1999a). Therefore, reduction in its expression might be detrimental to the cell. 
In fact, a study in fibroblasts from SCA3 patients by Zijlstra et al showed that SCA3 
patients with comparatively lower levels of DNAJB1 in their fibroblasts had an earlier age 
of onset of the disease symptoms independent of the CAG repeat length (Zijlstra et al, 
2010).  Several miRNAs predicted to target DNAJB1 also target other mRNAs. Hence, it 
is possible that the reduction in DNAJB1 mRNA levels is the result of an ‘off-target’ 
effect in which miRNAs targeting DNAJB1 were upregulated by the cell to control the 
expression of some other mRNA. Strategies to prevent miRNA targeting of DNAJB1 
mRNA might prove beneficial in SCA3 by preventing the downregulation of DNAJB1 
mRNA and protein and thereby decreasing the formation of ATXN3 aggregates and the 
associated toxicity. There are several methods to inhibit specific miRNAs such as the use 
of antisense oligonucleotides, miRNA sponges or RNA decoys delivered via lentiviruses 
(Davis et al, 2006; Ebert et al, 2007; Haraguchi et al, 2009). Some of these strategies, such 
as the antisense oligonucleotides have also been put to a therapeutic use (Janssen et al, 
2013). Therefore, the inhibition of specific miRNAs targeting DNAJB1 might be the basis 
of a new therapeutic approach to tackle SCA3 pathogenesis. 
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Concluding remarks 
 
In conclusion, several miRNAs that target the mRNAs of proteins that are disease 
modifiers in SCA3 were identified. These miRNAs might play a role in SCA3 disease 
progression. Overexpression of the specific miRNAs targeting neurotoxic proteins, using 
molecules mimicking their targeting ability or conversely blocking the activity of specific 
miRNAs that target neuroprotective proteins could be used as therapeutic strategy to alter 
disease progression at different stages. Overexpression of the miRNAs targeting ATXN3 
might prevent the toxic effects of the presence of the mutant protein. Likewise, 
overexpression of miRNAs targeting MID1 might arrest the translation of the expanded 
ATXN3 mRNA into the mutant ATXN3 protein. On the other hand, blocking the activity 
of miRNAs targeting DNAJB1 which protects the cells against the toxic effects of the 
mutant ATXN3 protein might be beneficial to the counter SCA3 toxicity.  
Future studies are needed to understand several aspects of miRNA targeting in SCA3. It 
would be necessary to verify if the targeting of the above mentioned proteins by the 
specific miRNAs occurs in vivo and its resulting influence on disease pathology. Also 
helpful would be the identification of further miRNAs that target the expression of each of 
the proteins included in this study. In case of the neurotoxic proteins ATXN3 and MID1, 
this would be instrumental in defining a pool of miRNAs that together might be able to 
exert a stronger inhibitory effect on the expression of these proteins in vivo. Consequently, 
another part of future studies would be to test the in vivo side effects of the use of such a 
pool of miRNAs considering the possibility of off-target effects.  
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Appendix 
List of genes upregulated in iPSC-derived neurons from SCA3 patients in comparison to 
iPSC-derived neurons from healthy controls. Genes have been arranged in descending 
order of fold change. 
Gene symbol Gene name Fold change 
in iPSC-
derived 
SCA3 
neurons 
FDR P-
value 
Genes upregulated in SCA3 neurons 
ELAVL2 
ELAV like neuron-specific RNA 
binding protein 2 4.94 8.37E-03 
KIAA1549L KIAA1549-like 4.3 0.04 
ANK3 
ankyrin 3, node of Ranvier (ankyrin 
G) 3.96 2.26E-03 
DCC DCC netrin 1 receptor 3.81 0.02 
MEX3A 
mex-3 RNA binding family member 
A  3.37 1.96E-04 
KCNQ2 
potassium channel, voltage gated 
KQT-like subfamily Q, member 2 3.35 0.02 
DIRAS2 
DIRAS family, GTP-binding RAS-
like 2 3.3 1.42E-03 
KLF7 Kruppel-like factor 7 3.07 0.01 
MAP2 microtubule-associated protein 2 2.99 0.05 
ST8SIA2 
ST8 alpha-N-acetyl-neuraminide 
alpha-2,8-sialyltransferase 2 2.79 0.02 
GPC2 glypican 2 2.67 0.01 
SLC38A1 solute carrier family 38, member 1  2.58 0.02 
PTBP2 
polypyrimidine tract binding protein 
2 2.54 0.02 
TRIB2 tribbles pseudokinase 2 2.53 3.02E-04 
AKAP6 A kinase (PRKA) anchor protein 6 2.43 0.02 
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MAP1B microtubule-associated protein 1B 2.35 6.67E-03 
STK39 serine threonine kinase 39 2.34 0.04 
STMN1 stathmin 1 2.21 0.03 
NR2F1 
nuclear receptor subfamily 2, group 
F, member 1 2.17 0.02 
NDRG4 NDRG family member 4 2.16 9.14E-03 
TSPYL4 TSPY-like 4 2.08 1.51E-03 
DTX4 deltex 4, E3 ubiquitin ligase 1.93 1.27E-04 
MLLT11 myeloid/lymphoid or mixed-lineage 1.9 0.05 
BEX1 brain expressed, X-linked 1 1.86 2.38E-10 
SEMA6A 
sema domain, transmembrane domain 
(TM), and cytoplasmic domain, 
(semaphorin) 6A 1.84 8.44E-03 
CYFIP2 
cytoplasmic FMR1 interacting protein 
2 1.78 0.02 
RUFY3 RUN and FYVE domain containing 3 1.73 4.23E-03 
KLC1 kinesin light chain 1 1.73 0.01 
DYNC1H1 dynein, cytoplasmic 1, heavy chain 1 1.64 0.01 
ATAT1 alpha tubulin acetyltransferase 1 1.63 0.03 
GTF2I general transcription factor IIi 1.62 0.01 
RTN4 reticulon 4 1.61 8.84E-03 
PARP6 
poly (ADP-ribose) polymerase 
family, member 6 1.58 0.04 
MATR3 matrin 3 1.53 1.96E-04 
PGD phosphogluconate dehydrogenase 1.52 1.74E-04 
PITPNA 
phosphatidylinositol transfer protein, 
alpha 1.52 0.04 
SCRN1 secernin 1 1.46 4.39E-03 
YWHAQ 
tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation protein, 
theta 1.44 9.95E-03 
PSAT1 phosphoserine aminotransferase 1 1.37 0.03 
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GNB1 
guanine nucleotide binding protein (G 
protein), beta polypeptide 1 1.28 6.36E-03 
GDI1 GDP dissociation inhibitor 1 1.23 3.18E-04 
 
List of genes downregulated in iPSC-derived neurons from SCA3 patients in comparison 
to iPSC-derived neurons from healthy controls. Genes have been arranged in descending 
order of fold change. 
Gene symbol Gene name Fold change 
in iPSC-
derived 
SCA3 
neurons 
FDR P-
value 
Genes downregulated in SCA3 neurons 
COLEC12 collectin sub-family member 12 -24.41 4.80E-15 
SERPINF1 serpin peptidase inhibitor, clade F 
(alpha-2 antiplasmin, pigment 
epithelium derived factor), member 1 
-14.26 4.10E-07 
LUM lumican -10.29 6.29E-38 
EFEMP2 EGF containing fibulin-like 
extracellular matrix protein 2 
-6.81 7.01E-04 
FAM176C eva-1 homolog C -5.82 0.05 
CCDC164 dynein regulatory complex subunit 1 -5.56 0.02 
IGFBP4 insulin-like growth factor binding 
protein 4 
-5.13 0.02 
AEBP1 AE binding protein 1 -4.89 6.44E-06 
ANXA1 annexin A1 -4 0.02 
IFITM3 interferon induced transmembrane 
protein 3 
-3.7 3.28E-03 
RRBP1 ribosome binding protein 1 -3.55 1.13E-03 
RRAS  related RAS viral (r-ras) 
oncogene homolog 
-3.49 0.01 
PTRF polymerase I and transcript release 
factor 
-3.37 9.95E-03 
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FLNB filamin B, beta -3.34 8.03E-03 
IER3 immediate early response 3 -3.29 0.03 
PLTP phospholipid transfer protein -3.06 1.27E-03 
TIMP1 TIMP metallopeptidase inhibitor 1 -3.01 2.57E-04 
FOSB FBJ murine osteosarcoma viral 
oncogene homolog B 
-2.99 0.03 
MYH9 myosin, heavy chain 9, non-muscle -2.67 3.36E-03 
SERPINB6 serpin peptidase inhibitor, clade B 
(ovalbumin), member 6 
-2.66 0.05 
DNAJB1 DnaJ (Hsp40) homolog, subfamily B, 
member 1 
-2.56 5.73E-04 
CTSB cathepsin B -2.16 1.03E-05 
CD164 CD164 molecule, sialomucin -2.1 1.27E-04 
CETN2 centrin, EF-hand protein, 2 -1.94 0.03 
NELF NMDA receptor synaptonuclear 
signaling and neuronal migration 
factor 
-1.79 7.40E-03 
CTNNA1 catenin (cadherin-associated protein), 
alpha 1, 102kDa 
-1.69 2.26E-03 
PAM peptidylglycine alpha-amidating 
monooxygenase 
-1.69 0.04 
RPS12 ribosomal protein S12 -1.52 6.65E-07 
RPS9 ribosomal protein S9 -1.45 0.03 
PSAP prosaposin -1.44 1.25E-05 
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List of miRNAs upregulated in iPSC-derived neurons from SCA3 patients in comparison 
to iPSC-derived neurons from healthy controls. miRNAs have been arranged in 
descending order of fold change. 
 
miRNA name 
Fold change in iPSC 
derived SCA3 neurons 
 
FDR P-value 
miRNAs upregulated in SCA3 neurons 
hsa-miR-431-5p 586.6214 1.27E-07 
hsa-miR-337-5p 352.2233 3.55E-06 
hsa-miR-770-5p 191.9895 7.60E-07 
hsa-miR-376a-3p 182.4585 1.78E-06 
hsa-miR-539-5p 134.6055 7.88E-05 
hsa-miR-432-5p 85.25497 6.68E-07 
hsa-miR-432-3p 84.53678 2.02E-03 
hsa-miR-541-5p 83.10655 3.44E-02 
hsa-miR-127-3p 80.14982 6.16E-13 
hsa-miR-541-3p 78.95533 4.87E-04 
hsa-miR-337-3p 74.32188 3.41E-08 
hsa-miR-136-5p 66.85646 2.62E-10 
hsa-miR-380-5p 66.44027 2.40E-03 
hsa-miR-299-5p 66.33228 3.67E-09 
hsa-miR-369-5p 65.50373 1.28E-09 
hsa-miR-127-5p 65.33154 1.21E-11 
hsa-miR-409-3p 62.79913 2.31E-06 
hsa-miR-154-5p 61.49923 1.98E-09 
hsa-miR-136-3p 58.97185 6.01E-12 
hsa-miR-485-3p 54.48456 7.84E-07 
hsa-miR-654-3p 54.26493 1.61E-08 
hsa-miR-380-3p 52.58121 1.28E-09 
hsa-miR-495-3p 51.78691 1.98E-09 
hsa-miR-379-3p 51.31836 8.21E-09 
hsa-miR-409-5p 50.65953 7.99E-04 
hsa-miR-433 50.51679 9.45E-06 
Appendix    
104 
 
hsa-miR-758-3p 49.5244 8.13E-09 
hsa-miR-134 48.39775 2.92E-07 
hsa-miR-369-3p 48.19559 4.15E-10 
hsa-miR-379-5p 48.05916 2.62E-10 
hsa-miR-377-5p 47.36093 6.32E-07 
hsa-miR-382-3p 47.25587 3.38E-09 
hsa-miR-323b-3p 46.76528 3.01E-02 
hsa-miR-382-5p 45.61819 3.20E-07 
hsa-miR-494 45.15569 7.63E-07 
hsa-miR-370 45.14309 6.47E-06 
hsa-miR-323a-3p 43.38047 5.32E-06 
hsa-miR-1197 42.06295 6.41E-06 
hsa-miR-668 41.84241 1.86E-03 
hsa-miR-654-5p 41.30734 7.63E-07 
hsa-miR-544a 40.98868 2.50E-02 
hsa-miR-431-3p 40.23896 1.45E-08 
hsa-miR-376b-5p 39.76311 3.05E-02 
hsa-miR-411-5p 39.52897 2.62E-10 
hsa-miR-1185-5p 39.2931 1.09E-09 
hsa-miR-381-5p 39.1471 3.45E-02 
hsa-miR-889 38.68175 2.62E-10 
hsa-miR-487b 38.63271 1.28E-09 
hsa-miR-485-5p 38.617 6.96E-07 
hsa-miR-411-3p 38.05624 3.38E-09 
hsa-miR-410 37.85289 1.00E-05 
hsa-miR-376c-3p 37.81475 1.05E-09 
hsa-miR-1185-1-3p 37.36638 3.41E-08 
hsa-miR-656 36.59561 9.33E-09 
hsa-miR-376a-5p 36.54073 2.30E-04 
hsa-miR-1185-2-3p 36.33916 6.35E-04 
hsa-miR-381-3p 35.94446 3.26E-10 
hsa-miR-329 35.7301 7.63E-08 
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hsa-miR-377-3p 35.65163 3.41E-08 
hsa-miR-376b-3p 33.61442 1.72E-07 
hsa-miR-299-3p 33.5104 2.86E-09 
hsa-miR-539-3p 32.90574 2.01E-09 
hsa-miR-487a 29.85199 6.70E-09 
hsa-miR-543 25.32928 4.73E-04 
hsa-miR-496 25.30281 5.99E-05 
hsa-miR-758-5p 21.16692 9.54E-03 
hsa-miR-493-5p 20.73649 3.19E-07 
hsa-miR-493-3p 20.04763 4.52E-07 
hsa-miR-655 19.30396 1.86E-05 
hsa-miR-2113 6.406751 2.18E-03 
hsa-miR-490-3p 4.952 2.08E-03 
 
List of miRNAs downregulated in iPSC-derived neurons from SCA3 patients in 
comparison to iPSC-derived neurons from healthy controls. miRNAs have been arranged 
in descending order of fold change. 
miRNA name Fold change in iPSC 
derived SCA3 neurons 
FDR P-value 
miRNAs downregulated in SCA3 neurons 
hsa-miR-449a -108.2534889 1.78E-03 
hsa-miR-449c-5p -93.32553078 9.54E-03 
hsa-miR-449b-5p -80.34681096 1.78E-03 
hsa-miR-199a-5p -66.25275354 3.01E-02 
hsa-miR-4490 -65.61140287 3.85E-03 
hsa-miR-199a-3p -61.29128195 3.47E-02 
hsa-miR-199b-3p -61.29128195 3.47E-02 
hsa-miR-199b-5p -48.63167017 4.46E-02 
hsa-miR-2114-5p -19.71020476 2.19E-03 
hsa-miR-143-3p -17.50185064 5.00E-02 
hsa-miR-193a-3p -13.50312411 2.02E-02 
hsa-miR-145-5p -12.31148516 4.63E-02 
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hsa-miR-2114-3p -12.08693102 1.17E-03 
hsa-miR-1266 -4.295350381 3.81E-02 
hsa-miR-1269a -4.090803361 8.91E-03 
hsa-miR-184 -3.930027022 2.27E-02 
hsa-miR-190b -3.869430519 2.55E-02 
hsa-miR-27b-5p -3.524804277 2.55E-02 
hsa-miR-23b-3p -3.287689506 3.47E-02 
 
Representation of the binding of miR-9, miR-125a-5p, miR-181c (two sites) and miR-
383 to ATXN3 3’UTR at their predicted binding sites. In each figure, the binding of the 
miRNAs to the wild type ATXN3 3’UTR is shown in (A), while the disruption to binding 
caused by mutations at two nucleotides in the miRNA binding sites in ATXN3 3’UTR is 
shown in (B). 
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Representation of the binding of miR-374a-5p, miR-542-3p to MID1 3’UTR at their 
predicted binding sites. In each figure, the binding of the miRNAs to the wild type MID1 
3’UTR is shown in (A), while the disruption to binding caused by mutations at two 
nucleotides in the miRNA binding sites in MID1 3’UTR is shown in (B). 
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Representation of the binding of miR-143, miR-449a, miR-370 (two sites) to DNAJB1 
3’UTR at their predicted binding sites. In each figure, the binding of the miRNAs to the 
wild type DNAJB1 3’UTR is shown in (A), while the disruption to binding caused by 
mutations at two nucleotides in the miRNA binding sites in DNAJB1 3’UTR is shown in 
(B). 
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